(this["webpackJsonpumms-app"]=this["webpackJsonpumms-app"]||[]).push([[0],{56:function(e,o,n){},57:function(e,o,n){},66:function(e){e.exports=JSON.parse('{"drugs":[{"id":"1","name":"Yescarta\xae (Axicabtagene Ciloleucel)","packageInsertURL":"https://www.fda.gov/media/108377/download","gradeTypes":[{"name":"CRS Toxicity (Cytokine Release Syndrome)","gradeSource":"Graded using CRS grading criteria from Lee et al., 2014","grades":[{"name":"Grade 1","description":"Symptoms require symptomatic treatment only (e.g. fever, nausea, fatigue, headache, myalgia, malaise)","response":"Evaluate and treat for other causes of fever\\nMonitor and treat symptomatically\\rIf no improvement after 24 hours: *Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\tIf improving, discontinue *Tocilizumab*\\nIf no improvement after 3 days: Administer one dose of *Dexamethasone* 10 mg IV","followup":null},{"name":"Grade 2","description":"Symptoms require and respond to moderate intervention.\\nOxygen requirement less than 40% FiO2 or hypotension responsive to fluids or low dose of one vasopressor or Grade 2 organ toxicity","response":"Evaluate and treat for other causes of fever, hypoxia, and hypotension\\nMonitor and treat symptomatically\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed if no clinical improvement\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\n*Dexamethasone* 10 mg x IV once daily\\nShould be monitored with continuous cardiac telemetry and pulse oximetry\\rIf improving continue until severity is Grade 1 or less and quickly taper\\nIf not improving increase *Dexamethasone* to the appropriate higher grade\\nIf improving, discontinue *tocilizumab*","followup":null},{"name":"Grade 3","description":"Symptoms require and respond to aggressive intervention.\\nOxygen requirement greater than 40% FiO2 or hypotension requiring high dose or multiple vasopressors or Grade 3 organ toxicity or Grade 4 transaminitis","response":"Evaluate and treat for other causes of fever, hypoxia, and hypotension\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed if no clinical improvement\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\n*Dexamethasone* 10 mg IV three times a day\\nShould be monitored with continuous cardiac telemetry and pulse oximetry\\nConsider intensive care unit level monitoring and supportive therapy\\nConsider echocardiogram\\rIf improving decrease to *dexamethasone* 10 mg IV daily per Grade 2 until severity is Grade1 or less and quickly taper\\nIf improving, discontinue *tocilizumab*\\nIf not improving manage per Grade 4","followup":null},{"name":"Grade 4","description":"Life threatening symptoms.\\nRequirements for ventilator support, continuous veno-venous hemodialysis (CVVHD), or Grace 4 organ toxicity (excluding transaminitis)","response":"Evaluate and treat for other causes of fever, hypoxia, and hypotension\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed if no clinical improvement\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\n*Methylprednisolone* 1000 mg IV daily for three days\\nIntensive care unit level monitoring and supportive therapy\\nConsider echocardiogram\\rIf improving decrease corticosteroids to the appropriate Grade until severity is Grade1 or less and taper as clinically appropriate\\nIf not improving *methylprednisolone* 1000 mg IV, 2-3 times a day or alternative therapy (Alternate therapy includes (but is not limited to): anakinra, siltuximab, ruxolitinib, cyclophosphamide, IVIG and ATG)","followup":null}]},{"name":"NeuroToxicity","gradeSource":"Graded using NCI CTCAE","grades":[{"name":"Grade 1","description":"Somnolence - mild drowsiness or sleepiness\\nConfusion - mild disorientation \\nEncephalopathy - mild limiting of ADLs \\nDysphasia - not impairing ability to communicate","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Evaluate and treat for other causes of fever, etc.\\nMonitor and treat symptomatically\\nConsider non-sedating anti-seizure prophylaxis with e.g. *levetiracetam* \\nGive *dexamethasone* 10 mg IV x 1 dose\\nRule out other causes of neurological signs and symptoms and provide supportive care\\rIf no improvement after 24 hours: *tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed if no clinical improvement\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\tIf improving, discontinue *tocilizumab*\\nIf not improving after 2 days, repeat dexamethasone 10 mg IV"},{"name":"No","response":"Consider non-sedating anti-seizure prophylaxis with e.g. *Levetiracetam*\\nGive *Dexamethasone* 10 mg IV\\nRule out other causes of neurological signs and symptoms and provide supportive care\\rIf not improving after 2 days, repeat *Dexamethasone* 10 mg IV"}]}},{"name":"Grade 2","description":"Somnolence - moderate, limiting instrumental ADLs\\n Confusion - moderate disorientation Encephalopathy - limiting instrumental ADLs\\n Dysphasia - moderate impairing ability to communicate spontaneously \\n ","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Consider non-sedating anti-seizure prophylaxis with e.g. *Levetiracetam*\\nGive *Dexamethasone* 10 mg IV every six hours\\nRule out other causes of neurological signs and symptoms and provide supportive care\\nMonitor with continuous cardiac telemetry and pulse oximetry\\nEvaluate and treat for other causes of fever, hypoxia, and hypotension\\n*Tocilizumab* 8mg/kg IV over 1 hr. (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed if no clinical improvement\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\rIf improving, discontinue *Tocilizumab*\\nIf improving, continue corticosteroids until the severity is Grade 1 or less, then quickly taper as appropriate.\\nIf not improving, manage as appropriate higher grade"},{"name":"No","response":"Consider non-sedating anti-seizure prophylaxis with e.g. *Levetiracetam*\\nGive *Dexamethasone* 10 mg IV four times a day\\nMonitor with continuous cardiac telemetry and pulse oximetry\\nRule out other causes of neurological signs and symptoms and provide supportive care\\rIf improving, continue corticosteroids until the severity is Grade 1 or less, then quickly taper as appropriate\\nIf not improving, manage as appropriate higher grade"}]}},{"name":"Grade 3","description":"Somnolence - obtundation or stupor \\nConfusion - severe disorientation \\nEncephalopathy - limiting self-care ADLs \\nDysphasia - severe receptive or expressive characteristics, impairing ab ability to read, write or communicate intelligibly ","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Consider non-sedating anti-seizure prophylaxis with e.g. *Levetiracetam* \\nGive *Methylprednisolone* 1 gram IV daily\\nRule out other causes of neurological signs and symptoms and provide supportive care.\\nEvaluate and treat for other causes of fever, hypoxia, and hypotension\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed if no clinical improvement\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nShould be monitored with continuous cardiac telemetry and pulse oximetry\\nConsider intensive care unit level monitoring and supportive therapy\\nConsider echocardiogram\\rIf improving, manage as lower grade and continue corticosteroids until the severity is Grade 1 or less, then taper as appropriate\\nIf improving, discontinue *Tocilizumab*\\nIf not improving, manage as Grade 4"},{"name":"No","response":"Consider non-sedating anti-seizure prophylaxis with e.g. *Levetiracetam*\\nGive *Methylprednisolone* 1gram IV daily\\nRule out other causes of neurological signs and symptoms and provide supportive care\\nConsider intensive care unit level monitoring and supportive therapy\\rIf improving, manage as lower grade and continue corticosteroids until the severity is Grade 1 or less, then taper as appropriate\\nIf not improving, manage as Grade 4"}]}},{"name":"Grade 4","description":"Life threatening consequences \\nUrgent intervention indicated\\nRequirement for mechanical ventilation \\nConsider cerebral edema","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Consider non-sedating anti-seizure prophylaxis with e.g. *Levetiracetam*\\nGive *Methylprednisolone* 1 gram IV  twice per day\\nRule out other causes of neurological signs and symptoms and provide supportive care\\nEvaluate and treat for other causes of fever, hypoxia, and hypotension\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed if no clinical improvement\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nIntensive care unit level monitoring and supportive therapy\\nConsider echocardiogram\\rIf improving, manage as lower grade and continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate\\nIf improving, discontinue *Tocilizumab*\\nIf not improving, consider *Methylprednisolone* 1 gram IV three times a day or alternate therapy (i.e. Anakinra, Siltuximab, Ruxolitinib, Cyclophosphamide, IVIG and ATG)"},{"name":"No","response":"Consider non-sedating anti-seizure prophylaxis with e.g. *Levetiracetam* \\nGive *Methylprednisolone* 1gram IV twice per day\\nRule out other causes of neurological signs and symptoms and provide supportive care\\nIntensive care unit level monitoring and supportive therapy\\rIf improving, continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate\\nIf not improving, consider *Methylprednisolone* 1 gram IV three times a day or alternate therapy (i.e. Anakinra, Siltuximab, Ruxolitinib, Cyclophosphamide, IVIG and ATG)"}]}}]}]},{"id":"2","name":"Breyanzi\xae (Lisocabtagene Maraleucel)","packageInsertURL":"https://www.fda.gov/media/145711/download","gradeTypes":[{"name":"CRS Toxicity (Cytokine Release Syndrome)","gradeSource":"Graded using CRS grading criteria from Lee et al., 2014","grades":[{"name":"Grade 1","description":"Symptoms require symptomatic treatment only (i.e. fever, nausea, fatigue, headache, myalgia, malaise)","response":null,"followup":{"name":"Onset < 72 hours after the infusion?","options":[{"name":"Yes (< 72 hours after infusion)","response":"Evaluate and treat for other causes of fever\\nMonitor and treat symptomatically\\nConsider *tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\nConsider *dexamethasone* 10 mg IV every 24 hours\\n\\tIf corticosteroids are initiated, continue corticosteroids for at least 3 doses or until complete resolution of symptoms, and consider corticosteroid taper"},{"name":"No (> 72 hours after infusion)","response":"Evaluate and treat for other causes of fever\\nMonitor and treat symptomatically"}]}},{"name":"Grade 2","description":"Symptoms require and respond to moderate intervention.\\n\\nOxygen requirement less than 40% FiO2 or hypotension responsive to fluids or low dose of one vasopressor or Grade 2 organ toxicity","response":null,"followup":{"name":"Onset < 72 hours after the infusion?","options":[{"name":"Yes (< 72 hours after infusion)","response":"Evaluate and treat for other causes of fever, hypoxia, and hypotension\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\tAfter 2 doses, consider alternative anti-cytokine agents\\nGive *dexamethasone* 10 mg x IV every 12 - 24 hours\\n\\tIf corticosteroids are initiated, continue corticosteroids for at least 3 doses or until complete resolution of symptoms, and consider corticosteroid taper\\nShould be monitored with continuous cardiac telemetry and pulse oximetry\\rNo improvement within 24 hours or rapid progression escalate *tocilizumab* and corticosteroids\\n\\tEscalate *dexamethasone* to 10- 20mg IV every 6-12 hours\\tIf continued progression or no improvement maximize *dexamethasone*, switch to *methylprednisolone* 2mg/kg IV if needed\\tIf corticosteroids are initiated, continue corticosteroids for at least 3 doses or until complete resolution of symptoms, and consider corticosteroid taper\\tRepeat *tocilizumab*\\n\\t\\fLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\t\\fAfter 2 doses, consider alternative anti-cytokine agents"},{"name":"No (> 72 hours after infusion)","response":"Evaluate and treat for other causes of fever, hypoxia, and hypotension\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\tAfter 2 doses, consider alternative anti-cytokine agents\\nConsider *dexamethasone* 10 mg x IV every 12 - 24 hours\\n\\tIf corticosteroids are initiated, continue corticosteroids for at least 3 doses or until complete resolution of symptoms, and consider corticosteroid taper\\nShould be monitored with continuous cardiac telemetry and pulse oximetry\\rNo improvement within 24 hours or rapid progression escalate *tocilizumab* and corticosteroids\\n\\tEscalate dexamethasone to 10- 20mg IV every 6-12 hours\\tIf continued progression or no improvement maximize *dexamethasone*, switch to *methylprednisolone* 2mg/kg IV if needed\\tRepeat *tocilizumab*\\n\\t\\fLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\t\\fAfter 2 doses, consider alternative anti-cytokine agents"}]}},{"name":"Grade 3","description":"Symptoms require and respond to aggressive intervention.\\n\\nOxygen requirement greater than 40% FiO2 or hypotension requiring high dose or multiple vasopressors or Grade 3 organ toxicity or Grade 4 transaminitis","response":"Evaluate and treat for other causes of fever, hypoxia, and hypotension\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen \\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses \\tAfter 2 doses, consider alternative anti-cytokine agents\\n*Dexamethasone* 10 mg x IV every 12 hours\\n\\tIf corticosteroids are initiated, continue corticosteroids for at least 3 doses or until complete resolution of symptoms, and consider corticosteroid taper\\nShould be monitored with continuous cardiac telemetry and pulse oximetry\\nConsider performing an echocardiogram\\rNo improvement within 24 hours or rapid progression escalate *tocilizumab* and corticosteroids\\n\\tEscalate *dexamethasone* to 10- 20mg IV every 6-12 hours\\n\\t\\fIf continued progression or no improvement maximize *dexamethasone* or switch to *methylprednisolone* 2mg/kg IV if needed\\t\\fIf corticosteroids are initiated, continue corticosteroids for at least 3 doses or until complete resolution of symptoms, and consider corticosteroid taper\\n\\tRepeat *tocilizumab*.\\n\\t\\fLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\t\\fAfter 2 doses, consider alternative anti-cytokine agents.","followup":null},{"name":"Grade 4","description":"Life threatening symptoms. including requirements for ventilator support, CVVHD, or Grace 4 organ toxicity (excluding Grade 4 transaminitis)","response":"Evaluate and treat for other causes of fever, hypoxia, and hypotension\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\tAfter 2 doses, consider alternative anti-cytokine agents\\n*Dexamethasone* 20 mg  IV every 6 hours\\n\\tIf corticosteroids are initiated, continue corticosteroids for at least 3 doses or until complete resolution of symptoms, and consider corticosteroid taper\\nConsider performing an echocardiogram\\nIntensive care unit level monitoring and supportive therapy\\rNo improvement within 24 hours or rapid progression escalate *tocilizumab* and corticosteroids\\n\\tMaximize *Dexamethasone* or switch to *methylprednisolone* 2mg/kg IV if needed\\n\\t\\fIf corticosteroids are initiated, continue corticosteroids for at least 3 doses or until complete resolution of symptoms, and consider corticosteroid taper\\n\\tRepeat *tocilizumab*.\\n\\t\\fLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses \\n\\t\\fAfter 2 doses, consider alternative anti-cytokine agents.","followup":null}]},{"name":"NeuroToxicity","gradeSource":"Graded using NCI CTCAE","grades":[{"name":"Grade 1","description":"Somnolence - mild drowsiness or sleepiness\\n\\nConfusion - mild disorientation \\n\\nEncephalopathy - mild limiting of ADLs \\n\\nDysphasia - not impairing ability to communicate","response":null,"followup":{"name":"Concurrent CRS Yes/No?","options":[{"name":"Yes","response":null,"followup":{"name":"Onset < 72 hours after the infusion?","options":[{"name":"Yes (< 72 hours after infusion)","response":"Start non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\nConsider *dexamethasone* 10 mg IV every 12-24 hours for 2-3 days\\nConsider *tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\nRule out other causes of neurological signs and symptoms and provide supportive care\\nEvaluate and treat for other causes of fever\\nMonitor and treat symptomatically                                                    "},{"name":"No (> 72 hours after infusion)","response":"Start non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\nRule out other causes of neurological signs and symptoms. and provide supportive care\\nEvaluate and treat for other causes of fever\\nMonitor and treat symptomatically"}]}},{"name":"No","response":null,"followup":{"name":"Onset < 72 hours after the infusion?","options":[{"name":"Yes (< 72 hours after infusion)","response":"Start non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\nConsider *dexamethasone* 10 mg IV every 12-24 hours for 2-3 days\\nRule out other causes of neurological signs and symptoms and provide supportive care"},{"name":"No (> 72 hours after infusion)","response":"Start non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\nRule out other causes of neurological signs and symptoms and provide supportive care"}]}}]}},{"name":"Grade 2","description":"Somnolence - moderate, limiting instrumental ADLs\\n\\n Confusion - moderate disorientation Encephalopathy - limiting instrumental ADLs\\n\\n Dysphasia - moderate impairing ability to communicate spontaneously \\n","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Start non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\n*Dexamethasone* 10 mg IV every 12 hours for 2-3 days, or longer for persistent symptoms\\n\\tConsider taper for a total corticosteroid exposure greater than 3 days\\nRule out other causes of neurological signs and symptoms and provide supportive care\\nEvaluate and treat for other causes of fever, hypoxia, and hypotension\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nShould be monitored with continuous cardiac telemetry and pulse oximetry\\rNo improvement within 24 hours or progression escalate *dexamethasone* dose and/or frequency to a maximum of 20mg IV every 6 hoursn\\nIf continued lack of improvement after another 24 hours or continued rapid progression, or life threatening complications arise give *methylprednisolone* 2mg/kg IV loading dose, followed by 2 mg/kg divided 4 times a day; taper within 7 days.\\nRepeat *tocilizumab*\\n\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses \\n\\tAfter 2 doses, consider alternative immunosuppressants                                        "},{"name":"No","response":"Start non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\n*Dexamethasone* 10 mg IV every 12 hours for 2-3 days, or longer for persistent symptoms\\n\\tConsider taper for a total corticosteroid exposure greater than 3 days\\nRule out other causes of neurological signs and symptoms and provide supportive care\\nShould be monitored with continuous cardiac telemetry and pulse oximetry\\rNo improvement within 24 hours or progression escalate *dexamethasone* dose and/or frequency to a maximum of 20mg IV every 6 hours\\nIf continued lack of improvement after another 24 hours or continued rapid progression, or life threatening complications arise give *methylprednisolone* 2mg/kg IV loading dose, followed by 2 mg/kg divided 4 times a day; taper within 7 days."}]}},{"name":"Grade 3","description":"Somnolence - obtundation or stupor \\n\\nConfusion - severe disorientation \\n\\nEncephalopathy - limiting self-care ADLs \\n\\nDysphasia - severe receptive or expressive characteristics, impairing ab ability to read, write or communicate intelligibly ","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Start non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\n*Dexamethasone* 10 mg-20 mg IV every 8-12 hours\\n\\tSteroids not recommended for isolated grade 3 headaches\\nRule out other causes of neurological signs and symptoms. Provide supportive care.\\nEvaluate and treat for other causes of fever, hypoxia, and hypotension\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nShould be monitored with continuous cardiac telemetry and pulse oximetry\\nConsider Intensive care unit level monitoring and supportive therapy\\nConsider performing an echocardiogram\\nmIf cerebral edema is suspected:\\n\\tConsider hyperventilation and hyperosmolar therapy\\tGive *methylprednisolone* 1-2grams IV; repeat every 24 hours as needed and taper as clinically indicated.\\tGive *cyclophosphamide* 1.5grams/m2 IV x 1 dose\\rNo improvement within 24 hours or rapid progression escalate *tocilizumab* and corticosteroids\\n\\tGive *dexamethasone* 10-20 mg IV every 6 to 12 hours\\n\\tRepeat *tocilizumab*.\\n\\t\\fLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\t\\fAfter 2 doses, consider alternative anti-cytokine agents\\n\\tIf no improvement or continued progression switch to *methylprednisolone* 2mg/kg IV loading dose, followed by 2 mg/kg divided 4 times a day; taper within 7 days"},{"name":"No","response":"Start non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\n*Dexamethasone* 10 mg \u2013 20 mg IV every 8-12 hours\\n\\tSteroids not recommended for isolated grade 3 headaches\\nRule out other causes of neurological signs and symptoms and provide supportive care\\nIntensive care unit level monitoring and supportive therapy\\nIf cerebral edema is suspected:\\n\\tConsider hyperventilation and hyperosmolar therapy \\tGive *methylprednisolone* 1-2grams IV; repeat every 24 hours as needed and taper as clinically indicated.\\tGive *cyclophosphamide* 1.5grams/m2 IV x 1 dose\\rNo improvement within 24 hours or rapid progression escalate *tocilizumab* and corticosteroids\\n\\tGive *dexamethasone* 10-20 mg IV every 6 to 12 hours\\tRepeat *tocilizumab*.\\n\\t\\fLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses \\t\\fAfter 2 doses, consider alternative anti-cytokine agents\\n\\tIf no improvement or continued progression switch to *methylprednisolone* 2mg/kg IV loading dose, followed by 2 mg/kg divided 4 times a day; taper within 7 days."}]}},{"name":"Grade 4","description":"Life threatening consequences \\n\\nUrgent intervention indicated\\n\\nRequirement for mechanical ventilation \\n\\nConsider cerebral edema","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Start non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\n*Dexamethasone* 20 mg  IV every 6 hours\\nRule out other causes of neurological signs and symptoms and provide supportive care.\\nEvaluate and treat for other causes of fever, hypoxia, and hypotension\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nIntensive care unit level monitoring and supportive therapy\\nIf cerebral edema is suspected:\\n\\tConsider hyperventilation and hyperosmolar therapy.\\tGive *methylprednisolone* 1-2grams IV; repeat every 24 hours as needed and taper as clinically indicated.\\tGive *cyclophosphamide* 1.5grams/m2 IV x 1 dose\\rNo improvement within 24 hours or rapid progression\\n\\tStart *methylprednisolone* 2mg/kg IV loading dose if needed, followed by 2 mg/kg divided 4 times a day; taper within 7 days.\\tRepeat *tocilizumab*.\\n\\t\\fLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\t\\fAfter 2 doses, consider alternative immunosuppressants"},{"name":"No","response":"Start non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\n*Dexamethasone* 20 mg  IV every 6 hours.\\nRule out other causes of neurological signs and symptoms and provide supportive care\\nIntensive care unit level monitoring and supportive therapy\\nIf cerebral edema is suspected:\\n\\tConsider hyperventilation and hyperosmolar therapy.\\tGive *methylprednisolone* 1-2grams IV; repeat every 24 hours as needed and taper as clinically indicated.\\tGive *cyclophosphamide* 1.5grams/m2 IV x 1 dose\\rNo improvement within 24 hours or rapid progression\\n\\tStart methylprednisolone 2mg/kg IV loading dose if needed, followed by 2 mg/kg divided 4 times a day; taper within 7 days."}]}}]}]},{"id":"3","name":"Abecma\xae (Idecabtagene Vicleucel)","packageInsertURL":"https://www.fda.gov/media/147055/download","gradeTypes":[{"name":"CRS Toxicity (Cytokine Release Syndrome)","gradeSource":"Graded using CRS grading criteria from Lee et al., 2014","grades":[{"name":"Grade 1","description":"Symptoms require symptomatic treatment only (i.e. fever, nausea, fatigue, headache, myalgia, malaise)","response":null,"followup":{"name":"Onset < 72 hours after the infusion?","options":[{"name":"Yes (< 72 hours after infusion)","response":"< 72 hours after the infusion\\n\\nEvaluate and treat for other causes of fever\\nMonitor and treat symptomatically\\nConsider *tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\nConsider *dexamethasone* 10 mg IV every 24 hours\\n\\tIf steroids are started continue for a minimum of 3 doses; taper over a maximum of 7 days\\nConsider anti-seizure prophylaxis with e.g. *levetiracetam*\\n"},{"name":"No (> 72 hours after infusion)","response":"> 72 hours after the infusion\\n\\nEvaluate and treat for other causes of fever\\nMonitor and treat symptomatically\\nConsider *dexamethasone* 10 mg IV every 24 hours \\n\\tIf steroids are started continue for a minimum of 3 doses; taper  over a maximum of 7 days\\nConsider anti-seizure prophylaxis with e.g. *levetiracetam*\\n"}]}},{"name":"Grade 2","description":"Symptoms require and respond to moderate intervention.\\n\\nOxygen requirement less than 40% FiO2 or hypotension responsive to fluids or low dose of one vasopressor or Grade 2 organ toxicity","response":"\\nEvaluate and treat for other causes of fever, hypoxia, and hypotension\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg).\\n\\t Repeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen \\tLimit to a max of 3 doses in 24-hour period; maximum total of 4 doses \\tAfter 2 doses, consider alternative anti-cytokine agents \\nConsider *Dexamethasone* 10 mg x IV every 12-24 hours\\tIf steroids are started continue for a minimum of 3 doses; taper over a maximum of 7 days\\nConsider anti-seizure prophylaxis with e.g *levetiracetam*\\nShould be monitored with continuous cardiac telemetry and pulse oximetry\\rNo improvement within 24 hours or rapid progression\\n\\tEscalate *dexamethasone* to 20mg IV every 6-12 hours\\n\\t\\fIf steroids are started continue for a minimum of 3 doses taper over a maximum of 7 days\\n\\tRepeat *tocilizumab*.\\n\\t\\fLimit to a max of 3 doses in 24-hour period; maximum total of 4 doses\\t\\fAfter 2 doses, consider alternative anti-cytokine agents.\\nContinued lack of improvement within 24 hours or continued rapid progression\\n\\tSwitch to *methylprednisolone* 2mg/kg IV followed by 2 mg/kg IV divided 4 times per day; taper as clinically indicated\\n\\t\\fIf steroids are started continue for a minimum of 3 doses taper over a maximum of 7 days\\n","followup":null},{"name":"Grade 3","description":"Symptoms require and respond to aggressive intervention.\\n\\nOxygen requirement greater than 40% FiO2 or hypotension requiring high dose or multiple vasopressors or Grade 3 organ toxicity or Grade 4 transaminitis","response":"Evaluate and treat for other causes of fever, hypoxia, and hypotension\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen\\tLimit to a max of 3 doses in 24-hour period; maximum total of 4 doses\\nAdminister *Dexamethasone* 10 mg  IV every 12 hours for a minimum of 3 doses\\n\\tTaper over a  maximum of 7 days\\nConsider anti-seizure prophylaxis with e.g. *levetiracetam*. Should be monitored with continuous cardiac telemetry and pulse oximetry\\nConsider intensive care unit level monitoring and supportive therapy\\rNo improvement within 24 hours or rapid progression\\n\\tEscalate *dexamethasone* to 20mg IV every 6-12 hours\\n\\t\\fIf steroids are started continue for a minimum of 3 doses taper over a maximum of 7 days\\n\\tRepeat *tocilizumab*:\\n\\t\\fAfter 2 doses, consider alternative anti-cytokine agents\\t\\fLimit to a max of 3 doses in 24-hour period; maximum total of 4 doses\\nContinued lack of improvement within 24 hours or continued rapid progression:\\n\\tSwitch to *methylprednisolone* 2mg/kg IV followed by 2 mg/kg IV divided 4 times per day; taper as clinically indicated\\n\\t\\fIf steroids are started continue for a minimum of 3 doses taper over a maximum of 7 days\\n","followup":null},{"name":"Grade 4","description":"Life threatening symptoms.\\n\\nRequirements for ventilator support, CVVHD, or Grace 4 organ toxicity (excluding Grade 4 transaminitis)","response":"Evaluate and treat for other causes of fever, hypoxia, and hypotension\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen\\tLimit to a max of 3 doses in 24-hour period; maximum total of 4 doses\\tAfter 2 doses, consider alternative anti-cytokine agents\\n*Dexamethasone* 20 mg  IV every 6 hours for a minimum of 3 doses\\n\\tTaper over a  maximum of 7 days\\nConsider anti-seizure prophylaxis with e.g. *levetiracetam*\\nIntensive care unit level monitoring and supportive therapy\\rIf no improvement within 24 hours\\n\\tConsider *methylprednisolone* 1-2 g IV, repeat every 24 hours if needed;\\n\\t\\fTaper as clinically indicated\\t\\for other anti-T cell therapies\\n\\tAfter 2 doses of tocilizumab, consider alternative anti-cytokine agent\\n\\t\\f Limit to a max of 3 doses in 24-hour period; maximum total of 4 doses\\n","followup":null}]},{"name":"NeuroToxicity","gradeSource":"Graded using NCI CTCAE","grades":[{"name":"Grade 1","description":"Somnolence - mild drowsiness or sleepiness\\n\\nConfusion - mild disorientation \\n\\nEncephalopathy - mild limiting of ADLs \\n\\nDysphasia - not impairing ability to communicate","response":null,"followup":{"name":"Onset < 72 hours after the infusion?","options":[{"name":"Yes (< 72 hours after infusion)","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Evaluate and treat for other causes of fever\\nMonitor and treat symptomatically\\nStart non-sedating anti-seizure prophylaxis with e.g. *levetiracetam* \\nConsider *dexamethasone* 10 mg IV every 12-24 hours for 2-3 days\\n\\tIf steroids are started continue for a minimum of 3 doses; taper  over a maximum of 7 days\\nRule out other causes of neurological signs and symptoms and provide supportive care\\nConsider *Tocilizumab* 8mg/kg (not to exceed 800 mg) IV over 1 hr.\\n"},{"name":"No","response":"Start non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\nConsider *dexamethasone* 10 mg IV every 12-24 hours for 2-3 days\\n\\tIf steroids are started continue for a minimum of 3 doses; taper  over a maximum of 7 days\\nRule out other causes of neurological signs and symptoms and provide supportive care\\n"}]}},{"name":"No (> 72 hours after infusion)","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Evaluate and treat for other causes of fever, etc.\\nMonitor and treat symptomatically\\nStart non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\nConsider *dexamethasone* 10 mg IV every 24 hours\\n\\tIf steroids are started continue for a minimum of 3 doses; taper  over a maximum of 7 days\\nRule out other causes of neurological signs and symptoms. Provide supportive care."},{"name":"No","response":"Start non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\nRule out other causes of neurological signs and symptoms. Provide supportive care.\\n"}]}}]}},{"name":"Grade 2","description":"Somnolence - moderate, limiting instrumental ADLs\\n\\n Confusion - moderate disorientation Encephalopathy - limiting instrumental ADLs\\n\\n Dysphasia - moderate impairing ability to communicate spontaneously \\n","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Start non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\n*Dexamethasone* 10 mg x IV every 12 hours for 2-3 days, or longer for persistent symptoms\\n\\tConsider taper for total steroid exposure greater than 3 days.\\tCorticosteroids are not recommended for isolated Grade 2 headaches\\nRule out other causes of neurological signs and symptoms and provide supportive care\\nEvaluate and treat for other causes of fever, hypoxia, and hypotension.\\n*Tocilizumab* 8mg/kg IV over 1 hr. (not to exceed 800 mg).\\n\\tRepeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen.\\tLimit to a max of 3 doses in 24-hour period; maximum total of 4 doses\\tAfter 2 doses of *tocilizumab*, consider alternative anti-cytokine agents\\nShould be monitored with continuous cardiac telemetry and pulse oximetry\\rNo improvement within 24 hours or rapid progression\\n\\tEscalate *dexamethasone* to 20mg IV every 6-hours\\n\\t\\fIf steroids are started continue for a minimum of 3 doses taper over a maximum of 7 days\\n\\tRepeat *tocilizumab*.\\n\\t\\fLimit to a max of 3 doses in 24-hour period; maximum total of 4 doses\\t\\fAfter 2 doses, consider alternative anti-cytokine agents.\\nContinued lack of improvement within 24 hours or continued rapid progression\\n\\tSwitch to *methylprednisolone* 2mg/kg IV followed by 2 mg/kg IV divided 4 times per day; taper as clinically indicated\\n\\t\\fIf steroids are started continue for a minimum of 3 doses taper over a maximum of 7 days"},{"name":"No","response":"Start non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\n*Dexamethasone* 10 mg x IV every 12 hours for 2-3 days, or longer for persistent symptoms\\n\\tConsider taper for total steroid exposure greater than 3 days.\\tCorticosteroids are not recommended for isolated Grade 2 headaches\\nRule out other causes of neurological signs and symptoms and provide supportive care\\rNo improvement within 24 hours or progression\\n\\tEscalate *dexamethasone* dose or frequency to 20mg IV every 6 hours"}]}},{"name":"Grade 3","description":"Somnolence - obtundation or stupor \\n\\nConfusion - severe disorientation \\n\\nEncephalopathy - limiting self-care ADLs \\n\\nDysphasia - severe receptive or expressive characteristics, impairing ab ability to read, write or communicate intelligibly ","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Start non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\nAdminister *Dexamethasone* 10 -20 mg  IV every 6-12 hours\\n\\tCorticosteroids are not recommended for isolated Grade 3 headaches\\nRule out other causes of neurological signs and symptoms and provide supportive care.\\nEvaluate and treat for other causes of fever, hypoxia, and hypotension\\n*Tocilizumab* 8mg/kg IV over 1 hr. (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen.\\n\\tLimit to a max of 3 doses in 24-hour period; maximum total of 4 doses\\nShould be monitored with continuous cardiac telemetry and pulse oximetry\\nConsider intensive care unit level monitoring and supportive therapy\\rNo improvement within 24 hours or progression\\n\\tEscalate to *methylprednisolone* 2mg/kg IV loading dose, followed by 2 mg/kg divided 4 times a day; taper within 7 days.\\tIf cerebral edema is suspected:\\n\\t\\fConsider hyperventilation and hyperosmolar therapy.\\t\\fGive *methylprednisolone* 1-2grams; repeat every 24 hours as needed and taper as clinically indicated.\\t\\fGive *cyclophosphamide* 1.5grams/m2 IV x 1 dose\\n\\tRepeat *tocilizumab*\\n\\t\\fAfter 2 doses of *tocilizumab*, consider alternative anti-cytokine agents .\\t\\fDo not exceed 3 doses of *tocilizumab* in 24 hours, or 4 doses in total.                                        "},{"name":"No","response":"Start non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\nDexamethasone 10 mg \u2013 20 mg IV every 6-12 hours\\n\\tTaper over a  maximum of 7 days\\tCorticosteroids are not recommended for isolated Grade 3 headaches\\nRule out other causes of neurological signs and symptoms and provide supportive care\\nConsider intensive care unit level monitoring and supportive therapy\\nIf cerebral edema is suspected: \\n\\tConsider hyperventilation and hyperosmolar therapy.\\tGive *methylprednisolone* 1-2grams; repeat every 24 hours as needed and taper as clinically indicated.\\tGive cyclophosphamide 1.5grams/m2 IV x 1 dose\\rNo improvement within 24 hours or progression\\n\\tEscalate to *methylprednisolone* 2mg/kg IV loading dose, followed by 2 mg/kg divided 4 times a day; taper within 7 days."}]}},{"name":"Grade 4","description":"Life threatening consequences \\n\\nUrgent intervention indicated\\n\\nRequirement for mechanical ventilation \\n\\nConsider cerebral edema","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Start non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\n*Dexamethasone* 20 mg IV every 6 hours\\n\\tCorticosteroids are not recommended for isolated Grade 3 headaches\\nRule out other causes of neurological signs and symptoms and provide supportive care\\n*Tocilizumab* 8mg/kg IV over 1 hr. (not to exceed 800 mg).\\n\\tRepeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen.\\tLimit to a max of 3 doses in 24-hour period; maximum total of 4 doses\\tAfter 2 doses of *tocilizumab*, consider alternative anti-cytokine agents\\nEvaluate and treat for other causes of fever, hypoxia, and hypotension\\nIntensive care unit level monitoring and supportive therapy\\nIf cerebral edema is suspected:\\n\\tConsider hyperventilation and hyperosmolar therapy.\\tGive *methylprednisolone* 1-2grams; repeat every 24 hours as needed and taper as clinically indicated.\\tGive *cyclophosphamide* 1.5grams/m2 IV x 1 dose\\rNo improvement within 24 hours or progression\\n\\tSwitch to *methylprednisolone* 1-2grams IV every 24 hours; taper as clinically indicated."},{"name":"No","response":"Start non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\n*Dexamethasone*  20 mg IV every 6 hours\\n\\tCorticosteroids are not recommended for isolated Grade 3 headaches\\nRule out other causes of neurological signs and symptoms and provide supportive care\\nIntensive care unit level monitoring and supportive therapy\\nIf cerebral edema is suspected:\\n\\tConsider hyperventilation and hyperosmolar therapy.\\tGive *methylprednisolone* 1-2grams; repeat every 24 hours as needed and taper as clinically indicated.\\n\\tGive *cyclophosphamide* 1.5grams/m2 IV x 1 dose\\rNo improvement within 24 hours or progression\\n\\tSwitch to *methylprednisolone* 1-2grams IV every 24 hours; taper as clinically indicated."}]}}]}]},{"id":"4","name":"Kymriah\xae (Tisagenlecleucel)","packageInsertURL":"https://www.fda.gov/media/107296/download","gradeTypes":[{"name":"CRS Toxicity (Cytokine Release Syndrome)","gradeSource":"Graded using CRS grading criteria from Lee et al., 2014","grades":[{"name":"Grade 1","description":"Low-grade fever, fatigue, anorexia","response":"Evaluate and treat for other causes of fever\\nMonitor and treat symptomatically\\nIf persistent (> 3 days) or refractory fever:\\rAdminister *Tocilizumab*\\n\\tPatient weight greater than or equal to 30 kg: 8mg/kg IV over 1 hr (not to exceed 800 mg)\\tPatient weight less than 30 kg: 12 mg/kg IV over 1 hr\\tRepeat every 8 hours as needed if no clinical improvement\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nIn no improvement within 24 hours of *tocilizumab*, administer *methylprednisolone* 2mg/kg/day IV\\n\\tuntil vasopressor and oxygen no longer needed then taper\\tIf not improving, manage at appropriate grade below","followup":null},{"name":"Grade 2 ","description":"Symptoms require and respond to moderate intervention Oxygen requirement < 40% or Hypotension responsive to fluids or low dose of one vasopressor or Grade 2 organ toxicity","response":"Evaluate and treat for other causes of fever, hypoxia, and hypotension\\nAdminister antipyretics, oxygen, intravenous fluids and/or low-dose vasopressors as needed.\\nMonitor and treat symptomatically\\nAdminister *Tocilizumab*\\n\\tPatient weight greater than or equal to 30 kg: 8mg/kg IV over 1 hr (not to exceed 800 mg)\\tPatient weight less than 30 kg: 12 mg/kg IV over 1 hr\\tRepeat every 8 hours as needed if no clinical improvement\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nIn no improvement within 24 hours of *tocilizumab*:\\r*methylprednisolone* 2mg/kg/day IV\\n\\tuntil vasopressor and oxygen no longer needed then taper\\tIf not improving, manage at appropriate grade below","followup":null},{"name":"Grade 3","description":"Symptoms require and respond to aggressive intervention Oxygen requirement \u2265 40% or Hypotension requiring high dose or multiple vasopressors or Grade 3 organ toxicity or Grade 4 transaminitis","response":"Evaluate and treat for other causes of fever, hypoxia, and hypotension\\nAdminister intravenous fluids, high dose or multiple vasopressors, high-flow oxygen, and/or other supportive care as needed.\\nAdminister *Tocilizumab*\\n\\tPatient weight greater than or equal to 30 kg: 8mg/kg IV over 1 hr (not to exceed 800 mg) \\tPatient weight less than 30 kg: 12 mg/kg IV over 1 hr\\tRepeat every 8 hours as needed if no clinical improvement\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nIf not improving:\\r\\n\\tConsider alternative immunosuppressants\\tIf not improving within 24 hours of *tocilizumab* give *methylprednisolone* 2mg/kg/day IV\\tuntil vasopressor and oxygen no longer needed then taper\\tIf not improving, manage per grade 4","followup":null},{"name":"Grade 4","description":"Life-threatening symptoms Requirement for ventilator support or Grade 4 organ toxicity (excluding transaminitis)","response":"Evaluate and treat for other causes of fever, hypoxia, and hypotension\\nAdminister intravenous fluids, high dose or multiple vasopressors, mechanical ventilation and/or other supportive care as needed.\\nAdminister *Tocilizumab*\\n\\tPatient weight greater than or equal to 30 kg: 8mg/kg IV over 1 hr (not to exceed 800 mg)\\tPatient weight less than 30 kg: 12 mg/kg IV over 1 hr\\tRepeat every 8 hours as needed if no clinical improvement\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nGive *Methylprednisolone* 1000 mg IV one to two time per day for 3 days\\n\\tIf not improving consider *methylprednisolone* two to three times a day or other immunosuppressants\\tContinue corticosteroids until Grade 1, then taper","followup":null}]},{"name":"NeuroToxicity","gradeSource":"Graded using NCI CTCAE","grades":[{"name":"Grade 1","description":"ICE score: 7-9 with no depressed level of consciousness","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Evaluate and treat for other causes of fever\\nMonitor and treat symptomatically\\nIf persistent (> 3 days) or refractory fever:\\rSupportive care including aspiration precautions and IV hydration\\nAdminister *Tocilizumab*\\n\\tPatient weight greater than or equal to 30 kg: 8mg/kg IV over 1 hr (not to exceed 800 mg)\\tPatient weight less than 30 kg: 12 mg/kg IV over 1 hr\\tCaution with repeated tocilizumab doses in patients with ICANS. \\tConsider adding corticosteroids to tocilizumab past the first dose\\tRepeat every 8 hours as needed if no clinical improvement\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nIn no improvement after the first dose of tocilizumab:\\rConsider *methylprednisolone* 2mg/kg/day IV\\n\\tuntil vasopressor and oxygen no longer needed then taper\\tIf not improving, manage at appropriate grade below"},{"name":"No","response":"Supportive care including aspiration precautions and IV hydration"}]}},{"name":"Grade 2","description":"Somnolence - moderate, limiting instrumental ADLs\\n\\n Confusion - moderate disorientation Encephalopathy - limiting instrumental ADLs\\n\\n Dysphasia - moderate impairing ability to communicate spontaneously \\n","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Supportive care including aspiration precautions and IV hydration\\nEvaluate and treat for other causes of fever, hypoxia, and hypotension\\nAdminister antipyretics, oxygen, intravenous fluids and/or low-dose vasopressors as needed.\\nMonitor and treat symptomatically\\nAdminister *Tocilizumab*\\n\\tPatient weight greater than or equal to 30 kg: 8mg/kg IV over 1 hr (not to exceed 800 mg)\\tPatient weight less than 30 kg: 12 mg/kg IV over 1 hr\\tRepeat every 8 hours as needed if no clinical improvement\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nConsider *dexamethasone* 10 mg IV every 6-12 hours or methylprednisolone equivalent (1 mg/kg IV every 12 hours) until the event is Grade 1 or less.\\nGive *dexamethasone* 10 mg IV every 6-12 hours or methylprednisolone equivalent (1 mg/kg IV every 12 hours) if If refractory to the first dose of tocilizumab until the event is Grade 1 or less\\nIf improving, taper corticosteroids.\\nIn no improvement within 24 hours of tocilizumab:\\r*methylprednisolone* 2mg/kg/day IV\\n\\tuntil vasopressor and oxygen no longer needed then taper\\tIf not improving, manage at appropriate grade below"},{"name":"No","response":"Supportive care including aspiration precautions and IV hydration\\nMonitor and treat symptomatically\\nConsider *dexamethasone* 10 mg IV every 6-12 hours or methylprednisolone equivalent (1mg/kg IV every 12 hours until Grade 1 or less.\\n\\tTaper corticosteroids"}]}},{"name":"Grade 3","description":"ICE score: 0-2 (A patient with an ICE score of 0 may be classified as Grade 3 ICANS if awake with global aphasia)( and/or Depressed level of consciousness awakening only to tactile stimulus and/or Any clinical seizure focal or generalized that resolves rapidly or nonconvulsive seizures on EEG that resolve with intervention and/or Focal or local edema on neuroimaging","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Supportive care including aspiration precautions and IV hydration\\nEvaluate and treat for other causes of fever, hypoxia, and hypotension\\nAdminister antipyretics, oxygen, intravenous fluids and/or low-dose vasopressors as needed.\\nMonitor and treat symptomatically\\nAdminister *Tocilizumab*\\n\\tPatient weight greater than or equal to 30 kg: 8mg/kg IV over 1 hr (not to exceed 800 mg)\\tPatient weight less than 30 kg: 12 mg/kg IV over 1 hr\\tRepeat every 8 hours as needed if no clinical improvement\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nGive *dexamethasone* 10 mg IV every 6-12 hours or methylprednisolone equivalent (1 mg/kg IV every 12 hours)\\n\\tContinue corticosteroids until grade 1 or less then taper\\tIf not improving manage as Grade 4"},{"name":"No","response":"Supportive care including aspiration precautions and IV hydration\\nMonitor and treat symptomatically\\nGive *dexamethasone* 10 mg IV every 6-12 hours or methylprednisolone equivalent (1mg/kg IV every 12 hours until Grade 1 or less."}]}},{"name":"Grade 4","description":"ICE score: 0* (patient is unarousable and unable to perform ICE) and/or Stupor or coma and/or Life-threatening prolonged seizure (> 5 minutes) or repetitive clinical or electrical seizures without return to baseline in between and/or Diffuse cerebral edema on neuroimaging, decerebrate or decorticate posturing or papilledema, cranial nerve VI palsy, or Cushing\u2019s triad","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Evaluate and treat for other causes of fever, hypoxia, and hypotension\\nAdminister intravenous fluids, high dose or multiple vasopressors, mechanical ventilation and/or other supportive care as needed.\\nAdminister *Tocilizumab*\\n\\tPatient weight greater than or equal to 30 kg: 8mg/kg IV over 1 hr (not to exceed 800 mg)\\tPatient weight less than 30 kg: 12 mg/kg IV over 1 hr\\tRepeat every 8 hours as needed if no clinical improvement\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nMonitor and treat seizures, status epilepticus, and cerebral edema as clinically indicated\\nGive *methylprednisolone* 1000 mg IV one to two times per day for three days.\\n\\tIf not improving consider methylprednisolone 1000 mg IV two to three times per day or alternate therapy which may include anakinra, siltuximab, ruxolitinib, cyclophosphamide, antithymocyte globulin, or intrathecal hydrocortisone (50 mg) plus methotrexate (12 mg).\\timmunosuppressants.\\tContinue corticosteroids until Grade 1, then taper"},{"name":"No","response":"Supportive care including mechanical ventilation for airway protection\\nMonitor and treat seizures, status epilepticus, and cerebral edema as clinically indicated\\nGive *methylprednisolone* 1000 mg IV one to two times per day for three days.\\n\\tIf not improving consider methylprednisolone 1000 mg IV two to three times per day or alternate immunosuppressants.\\tContinue corticosteroids until Grade 1, then taper"}]}}]}]},{"id":"5","name":"Tecartus\u2122 (Brexucabtagene Autoleucel)","packageInsertURL":"https://www.fda.gov/media/140409/download","gradeTypes":[{"name":"CRS Toxicity (Cytokine Release Syndrome)","gradeSource":"Graded using CRS grading criteria from Lee et al., 2014","grades":[{"name":"Grade 1","description":"Symptoms require symptomatic treatment only (i.e. fever, nausea, fatigue, headache, myalgia, malaise)","response":"Evaluate and treat for other causes of fever\\nMonitor and treat symptomatically\\rIf no improvement after 24 hours: *Tociluzumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n","followup":null},{"name":"Grade 2","description":"Symptoms require and respond to moderate intervention.\\nOxygen requirement less than 40% FiO2 or hypotension responsive to fluids or low dose of one vasopressor or Grade 2 organ toxicity","response":"Evaluate and treat for other causes of fever, hypoxia, and hypotension\\nMonitor and treat symptomatically\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg).\\n\\tRepeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nShould be monitored with continuous cardiac telemetry and pulse oximetry\\rIf improving, discontinue *tocilizumab*\\nIf not improving within 24 hours of starting *tocilizumab* then, manage per Grade 3 (give *methylprednisolone* 1mg/kg IV twice daily or equivalent *dexamethasone* 10 mg IV every 6 hours until Grade 1, then taper)\\n","followup":null},{"name":"Grade 3","description":"Symptoms require and respond to aggressive intervention.\\nOxygen requirement greater than 40% FiO2 or hypotension requiring high dose or multiple vasopressors or Grade 3 organ toxicity or Grade 4 transaminitis","response":"Evaluate and treat for other causes of fever, hypoxia, and hypotension\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nGive *methylprednisolone* 1mg/kg IV twice daily or equivalent *dexamethasone* 10 mg IV every 6 hours until Grade 1, then taper\\nShould be monitored with continuous cardiac telemetry and pulse oximetry\\nConsider intensive care unit level monitoring and supportive therapy\\nConsider echocardiogram\\rIf improving, discontinue *tocilizumab*,\\nIf improving taper corticosteroids\\nIf not improving, manage per Grade 4 (Give *methylprednisolone* 1000 mg IV  daily for 3 days)\\n","followup":null},{"name":"Grade 4","description":"Life threatening symptoms.\\nRequirements for ventilator support, CVVHD, or Grace 4 organ toxicity (excluding Grade 4 transaminitis)","response":"Evaluate and treat for other causes of fever, hypoxia, and hypotension\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nGive *methylprednisolone* 1000 mg IV  daily for 3 day\\nShould be monitored with continuous cardiac telemetry and pulse oximetry\\nIntensive care unit level monitoring and supportive therapy\\nConsider echocardiogram\\r\\nIf improving, discontinue *tocilizumab*\\nIf improving, taper corticosteroids, and manage per Grade 3. If  continuing to improve decrease to daily until severity is Grade1 or less and quickly taper\\nIf not improving, consider alternative immunosuppressants (Alternate therapy includes (but is not limited to): anakinra, siltuximab, ruxolitinib, cyclophosphamide, IVIG and ATG.)\\n","followup":null}]},{"name":"NeuroToxicity","gradeSource":"Graded using NCI CTCAE","grades":[{"name":"Grade 1","description":"Somnolence - mild drowsiness or sleepiness\\n\\nConfusion - mild disorientation \\n\\nEncephalopathy - mild limiting of ADLs \\n\\nDysphasia - not impairing ability to communicate","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Rule out other causes of neurological signs and symptoms and provide supportive care\\nMonitor and treat symptomatically\\nEvaluate and treat for other causes of fever, etc\u2026\\rIf not improvement after 24 hours: *Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n"},{"name":"No","response":"Rule out other causes of neurological signs and symptoms and provide supportive care\\nMonitor and treat symptomatically\\n"}]}},{"name":"Grade 2","description":"Somnolence - moderate, limiting instrumental ADLs\\n\\n Confusion - moderate disorientation Encephalopathy - limiting instrumental ADLs\\n\\n Dysphasia - moderate impairing ability to communicate spontaneously \\n","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Consider non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\nRule out other causes of neurological signs and symptoms and provide supportive care\\nEvaluate and treat for other causes of fever, hypoxia, and hypotension \\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg).\\n\\tRepeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen \\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nShould be monitored with continuous cardiac telemetry and pulse oximetry\\rIf improving, discontinue *tocilizumab*\\nIf not improving within 24 hours of starting *tocilizumab*\\n\\tGive *dexamethasone* 10 mg IV every 6 hours until Grade 1 or less, then taper corticosteroids \\nIf still not improving, manage as Grade 3\\n"},{"name":"No","response":"Consider non-sedating anti-seizure prophylaxis with e.g. *levetiracetam* \\nRule out other causes of neurological signs and symptoms and provide supportive care\\nShould be monitored with continuous cardiac telemetry and pulse oximetry\\nGive *dexamethasone* 10 mg IV every 6 hours until Grade 1 or less\\rIf improving taper corticosteroids"}]}},{"name":"Grade 3","description":"Somnolence - obtundation or stupor \\n\\nConfusion - severe disorientation \\n\\nEncephalopathy - limiting self-care ADLs \\n\\nDysphasia - severe receptive or expressive characteristics, impairing ab ability to read, write or communicate intelligibly ","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Consider non-sedating anti-seizure prophylaxis with e.g. *levetiracetam* \\nEvaluate and treat for other causes of fever, hypoxia, and hypotension \\nRule out other causes of neurological signs and symptoms and provide supportive care \\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg) \\n\\tRepeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen \\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses \\nGive *dexamethasone* 10 mg IV with the first dose of *tocilizumab* and repeat every 6 hours \\nShould be monitored with continuous cardiac telemetry and pulse oximetry \\nConsider intensive care unit level monitoring and supportive therapy \\nConsider echocardiogram \\rIf improving continue corticosteroids until Grade 1 or less, then \\nIf improving, discontinue *tocilizumab* and manage as Grade \\nIf not improving manage as Grade 4\\n"},{"name":"No","response":"Consider non-sedating anti-seizure prophylaxis with e.g. *levetiracetam* \\n *Dexamethasone* 10mg IV every 6 hours \\nShould be monitored with continuous cardiac telemetry and pulse oximetry \\nConsider intensive care unit level monitoring and supportive therapy \\nRule out other causes of neurological signs and symptoms and provide supportive care \\rIf improving, continue corticosteroids until grade 1 or less, then taper\\nIf not improving manage as Grade 4\\n"}]}},{"name":"Grade 4","description":"Life threatening consequences \\n\\nUrgent intervention indicated\\n\\nRequirement for mechanical ventilation \\n\\nConsider cerebral edema","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Consider non-sedating anti-seizure prophylaxis with e.g. *levetiracetam* \\nEvaluate and treat for other causes of fever, hypoxia, and hypotension \\nRule out other causes of neurological signs and symptoms and provide supportive care \\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg) \\n\\tRepeat every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen \\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses \\n*Methylprednisolone* 1000 mg IV daily starting with the first dose of *tocilizumab* and continue for 2 additional days \\nIntensive care unit level monitoring and supportive therapy \\nConsider echocardiogram\\rIf improving manage as Grade 3\\nIf not improving, consider alternate immunosuppressants (i.e. anakinra, siltuximab, ruxolitinib, cyclophosphamide, IVIG and ATG)\\n"},{"name":"No","response":"Consider non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\nRule out other causes of neurological signs and symptoms and provide supportive care\\nGive *methylprednisolone* 1000 mg IV daily for 3 days\\nIntensive care unit level monitoring and supportive therapy\\rIf improving manage as Grade 3\\nIf not improving, consider alternate immunosuppressants (i.e. anakinra, siltuximab, ruxolitinib, cyclophosphamide, IVIG and ATG)\\n"}]}}]}]},{"id":"6","name":"CARVYKTI\u2122 (ciltacabtagene autoleucel)","packageInsertURL":"https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/CARVYKTI-pi.pdf","gradeTypes":[{"name":"CRS Toxicity (Cytokine Release Syndrome)","gradeSource":"Graded using ASTCT 2019 grading system (Lee et al, 2019)","grades":[{"name":"Grade 1","description":"(Temperature \u226538\xb0C)","response":null,"followup":{"name":"> 72 hours after the infusion?","options":[{"name":"Yes","response":"Evaluate and treat for other causes of fever\\nConsider laboratory testing to monitor for disseminated intravascular coagulation, hematology parameters, as well as pulmonary, cardiac, renal, and hepatic function\\nMonitor and treat symptomatically\\nConsider anti-seizure prophylaxis with *levetiracetam*"},{"name":"No","response":"Evaluate and treat for other causes of fever\\nConsider laboratory testing to monitor for disseminated intravascular coagulation, hematology parameters, as well as pulmonary, cardiac, renal, and hepatic function\\nMonitor and treat symptomatically\\nConsider Tocilizumab 8mg/kg IV over 1 hr (not to exceed 800 mg)\\nConsider anti-seizure prophylaxis with *levetiracetam*"}]}},{"name":"Grade 2","description":"Symptoms require and respond to moderate intervention. Temperature \u226538\xb0Cc with: Hypotension not requiring vasopressors, and/or, Hypoxia requiring oxygen via canula or blow-by, or, Grade 2 organ toxicity (per NCI CTCAE ver. 5.0)","response":"Evaluate and treat for other causes of fever, hypoxia, and hypotension\\nConsider laboratory testing to monitor for disseminated intravascular coagulation, hematology parameters, as well as pulmonary, cardiac, renal, and hepatic function\\nMonitor and treat symptomatically\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg).\\n\\tRepeat every 8 hours as needed if not responsive to IV fluids up to 1 liter or increasing supplemental oxygen\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nConsider *dexamethasone* 10 mg IV  every 12-24 hours\\n\\tContinue corticosteroids use until the event is Grade 1 or less; taper steroids if total corticosteroid exposure is greater than 3 days\\nShould be monitored with continuous cardiac telemetry and pulse oximetry\\nConsider anti-seizure prophylaxis with *levetiracetam*\\nIf no improvement within 24 hours or rapid progression:\\rRepeat *tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg) and\\n\\tRepeat every 8 hours as needed if no clinical improvement\\tAfter two doses consider alternative anti-cytokine agents (i.e. monoclonal antibodies targeting cytokines)\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nIncrease *dexamethasone* to 20 mg IV every 6-12 hours\\n\\tContinue corticosteroids use until the event is Grade 1 or less; taper steroids if total corticosteroid exposure is greater than 3 days\\nIf no improvement within 24 hours or continued rapid progression, switch to *methylprednisolone* 2 mg/kg IV every 12 hours\\n\\tContinue corticosteroids use until the event is Grade 1 or less; taper steroids if total corticosteroid exposure is greater than 3 days\\nCRS refractory to first line interventions such as tocilizumab or tocilizumab and corticosteroids, consider alternate treatment options (i.e., higher corticosteroid dose, alternative anti-cytokine agents, e.g., anti-IL1 and/or anti-TNF\u03b1, anti-T cell therapies)\\n\\tRefractory CRS is characterized by fevers, end-organ toxicity (e.g., hypoxia, hypotension) not improving within 12 hours of first line interventions or development of HLH/MAS","followup":null},{"name":"Grade 3","description":"Symptoms require and respond to aggressive intervention. Temperature \u226538\xb0Cc with: Hypotension requiring one vasopressor with or without vasopressin, and/or, Hypoxia requiring oxygen via high-flow nasal canula(>6L/min), facemask, non-rebreather mask, or Venturi mask, or, Grade 3 organ toxicity or Grade 4 transaminitis (per NCI CTCAE ver. 5.0)","response":"Evaluate and treat for other causes of fever, hypoxia, and hypotension\\nConsider laboratory testing to monitor for disseminated intravascular coagulation, hematology parameters, as well as pulmonary, cardiac, renal, and hepatic function\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg).\\n\\tRepeat every 8 hours as needed if not responsive to IV fluids up to 1 liter or increasing supplemental oxygen\\tAfter two doses consider alternative anti-cytokine agents (i.e. monoclonal antibodies targeting cytokines)\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses \\n*Dexamethasone* 10 mg IV every 12 hours\\n\\tContinue corticosteroids use until the event is Grade 1 or less; taper steroids if total corticosteroid exposure is greater than 3 days\\nShould be monitored with continuous cardiac telemetry and pulse oximetry\\nConsider anti-seizure prophylaxis with *levetiracetam*\\nConsider intensive care unit level monitoring and supportive therapy\\nIf no improvement within 24 hours or rapid progression:\\rRepeat *tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg) and\\n\\tRepeat every 8 hours as needed if no clinical improvement\\tAfter two doses consider alternative anti-cytokine agents (i.e. monoclonal antibodies targeting cytokines)\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nIncrease *dexamethasone* to 20 mg IV every 6-12 hours\\n\\tContinue corticosteroids use until the event is Grade 1 or less; taper steroids if total corticosteroid exposure is greater than 3 days\\nIf no improvement within 24 hours or continued rapid progression, switch to *methylprednisolone* 2 mg/kg IV every 12 hours\\n\\tContinue corticosteroids use until the event is Grade 1 or less; taper steroids if total corticosteroid exposure is greater than 3 days\\nCRS refractory to first line interventions such as tocilizumab or tocilizumab and corticosteroids, consider alternate treatment options (i.e., higher corticosteroid dose, alternative anti-cytokine agents, e.g., anti-IL1 and/or anti-TNF\u03b1, anti-T cell therapies)\\n\\tRefractory CRS is characterized by fevers, end-organ toxicity (e.g., hypoxia, hypotension) not improving within 12 hours of first line interventions or development of HLH/MAS","followup":null},{"name":"Grade 4","description":"Life-threatening symptoms. Requirements for ventilator support, continuous veno-venous hemodialysis (CVVHD). Temperature \u226538\xb0Cc with: Hypotension requiring multiple vasopressors (excluding vasopressin), and/or, Hypoxia requiring positive pressure (e.g., CPAP, BiPAP, intubation, and mechanical ventilation), or, Grade 4 organ toxicity (excluding transaminitis) (per NCI CTCAE ver. 5.0)","response":"Evaluate and treat for other causes of fever, hypoxia, and hypotension\\nConsider laboratory testing to monitor for disseminated intravascular coagulation, hematology parameters, as well as pulmonary, cardiac, renal, and hepatic function\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg).\\n\\tRepeat every 8 hours as needed if no clinical improvement\\tAfter 2 doses, consider alternative anti-cytokine agents (i.e. monoclonal antibodies targeting cytokines)\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\n*Dexamethasone* 20 mg IV every 6 hours\\nIntensive care unit level monitoring and supportive therapy\\nConsider anti-seizure prophylaxis with *levetiracetam*\\nIf no improvement within 24 hours:\\rRepeat *tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n\\tRepeat every 8 hours as needed if no clinical improvement\\tAfter 2 doses, consider alternative anti-cytokine agents (i.e. monoclonal antibodies targeting cytokines)\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nIncrease *dexamethasone* to 20 mg IV every 6-12 hours\\nIf no improvement within 24 hours consider to *methylprednisolone* 1-2 g IV every 24 hours if needed; taper as clinically indicated or other immunosuppressants (e.g. other anti-T cell therapies)\\nCRS refractory to first line interventions such as tocilizumab or tocilizumab and corticosteroids, consider alternate treatment options (i.e., higher corticosteroid dose, alternative anti-cytokine agents, e.g., anti-IL1 and/or anti-TNF\u03b1, anti-T cell therapies)\\n\\tRefractory CRS is characterized by fevers, end-organ toxicity (e.g., hypoxia, hypotension) not improving within 12 hours of first line interventions or development of HLH/MAS","followup":null}]},{"name":"NeuroToxicity","gradeSource":"ASTCT 2019 grading system (Lee et.al, 2019)","grades":[{"name":"Grade 1","description":"ICE score 7-9 or depressed level of consciousness: awakens spontaneously","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Evaluate and treat for other causes of fever\\nConsider laboratory testing to monitor for disseminated intravascular coagulation, hematology parameters, as well as pulmonary, cardiac, renal, and hepatic function\\nMonitor and treat symptomatically\\nConsider non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\nConsider *dexamethasone* or equivalent 10 mg IV every 12 to 24 hours for 2-3 days\\nRule out other causes of neurological signs and symptoms. Provide supportive care\\nIf symptoms occurred < 72 hours from the infusion; Consider Tocilizumab 8mg/kg IV over 1 hr (not to exceed 800 mg)"},{"name":"No","response":"Consider non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\nConsider *dexamethasone* or equivalent 10 mg IV every 12 to 24 hours for 2-3 days,\\nRule out other causes of neurological signs and symptoms. Provide supportive care"}]}},{"name":"Grade 2","description":"ICE score-3-6 or depressed level of consciousness: awakens to voice","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Consider non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\nGive *dexamethasone* or equivalent 10 mg IV every 12 hours for 2-3 days, or longer if symptoms persist\\n\\tContinue corticosteroids use until the event is Grade 1 or less; taper steroids if total corticosteroid exposure is greater than 3 days\\nRule out other causes of neurological signs and symptoms. Provide supportive care.\\nShould be monitor with continuous cardiac telemetry and pulse oximetry\\nEvaluate and treat for other causes of fever, hypoxia, and hypotension\\nMonitor and treat symptomatically\\nConsider laboratory testing to monitor for disseminated intravascular coagulation, hematology parameters, as well as pulmonary, cardiac, renal, and hepatic function\\n*Tocilizumab* 8mg/kg IV over 1 hr. (not to exceed 800 mg).\\n\\tRepeat every 8 hours as needed if not responsive to IV fluids up to 1 liter or increasing supplemental oxygen\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\rIf no improvement after 24 hours or worsening neurologic toxicity, \\n\\tIncrease *dexamethasone* or equivalent to a maximum of 20 mg IV every 6 hours.\\n\\tRepeat *tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\n\\t\\fRepeat every 8 hours as needed if no clinical improvement\\t\\fAfter two doses consider alternative anti-cytokine agents (i.e. monoclonal antibodies targeting cytokines)\\t\\fLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses"},{"name":"No","response":"Consider non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\nGive *dexamethasone* or equivalent 10 mg IV every 12 hours for 2-3 days, or longer for persistent symptoms.\\n\\tContinue corticosteroids use until the event is Grade 1 or less; taper steroids if total corticosteroid exposure is greater than 3 days\\nRule out other causes of neurological signs and symptoms. Provide supportive care.\\rIf no improvement after 24 hours or worsening neurologic toxicity,\\n\\tIncrease *dexamethasone* or equivalent to a maximum of 20 mg IV every 6 hours."}]}},{"name":"Grade 3","description":"ICE score-0-2 (If ICE score is 0, but the patient is arousable (e.g., awake with global aphasia) and able to perform assessment)or depressed level of consciousness: awakens only to tactile stimulus,or seizures, either:\\nany clinical seizure, focal or generalized, that resolves rapidly, or\\nnon-convulsive seizures on EEG that resolve with intervention, or\\nraised intracranial pressure (ICP): focal/local edema on neuroimaging.","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Consider non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\nGive *dexamethasone* or equivalent 10-20 mg IV every 6 hours\\n\\tContinue corticosteroids use until the event is Grade 1 or less; taper steroids if total corticosteroid exposure is greater than 3 days\\nRule out other causes of neurological signs and symptoms and provide supportive care.\\nIntracranial hemorrhage with or without associated edema is not considered a neurotoxicity feature and is excluded from ICANS grading. It may be graded according to NCI CTCAE v5.0\\nEvaluate and treat for other causes of fever, hypoxia, and hypotension\\nConsider laboratory testing to monitor for disseminated intravascular coagulation, hematology parameters, as well as pulmonary, cardiac, renal, and hepatic function\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg).\\n\\tRepeat every 8 hours as needed if not responsive to IV fluids up to 1 liter or increasing supplemental oxygen\\tAfter two doses consider alternative anti-cytokine agents (i.e. monoclonal antibodies targeting cytokines)\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nShould be monitored with continuous cardiac telemetry and pulse oximetry\\nIf cerebral edema is suspected, consider hyperventilation and hyperosmolar therapy\\nConsider intensive care unit level monitoring and supportive therapy\\rIf no improvement after 24 hours or worsening neurologic toxicity,\\n\\tEscalate *dexamethasone* or equivalent dose to at least 20 mg every 6 hours\\tOr escalate to *methylprednisolone* 1-2 g IV q 24 hours; taper as clinically indicated\\tContinue corticosteroids use until the event is Grade 1 or less; taper steroids if total corticosteroid exposure is greater than 3 days\\tRepeat *tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\t\\fRepeat every 8 hours as needed if no clinical improvement\\t\\fAfter two doses consider alternative anti-cytokine agents (i.e. monoclonal antibodies targeting cytokines)\\t\\fLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses"},{"name":"No","response":"Consider non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\nGive *dexamethasone* or equivalent 10-20 mg IV every 6 hours\\n\\tContinue corticosteroids use until the event is Grade 1 or less; taper steroids if total corticosteroid exposure is greater than 3 days\\nRule out other causes of neurological signs and symptoms and provide supportive care.\\nIntracranial hemorrhage with or without associated edema is not considered a neurotoxicity feature and is excluded from ICANS grading. It may be graded according to NCI CTCAE v5.0\\nIf cerebral edema is suspected, consider hyperventilation and hyperosmolar therapy\\nConsider intensive care unit level monitoring and supportive therapy\\rIf no improvement after 24 hours or worsening neurologic toxicity,\\n\\tEscalate *dexamethasone* or equivalent dose to at least 20 mg every 6 hours\\tOr escalate to *methylprednisolone* 1-2 g IV q 24 hours; taper as clinically indicated"}]}},{"name":"Grade 4","description":"ICE score-0 (Patient is unarousable and unable to perform ICE assessment), or depressed level of consciousness either:\\n\\tpatient is unarousable or requires vigorous or repetitive tactile stimuli to arouse, or\\tstupor or coma\\nor seizures, either:\\n\\tlife-threatening prolonged seizure (>5 min), or\\trepetitive clinical or electrical seizures without return to baseline in between\\nor motor findings:\\n\\tdeep focal motor weakness such as hemiparesis or paraparesis\\nor raised ICP/cerebral edema, with signs/symptoms such as:\\n\\tdiffuse cerebral edema on neuroimaging, or\\tdecerebrate or decorticate posturing, or\\tcranial nerve VI palsy, or\\tpapilledema, or\\tCushing\u2019s triad","response":null,"followup":{"name":"Concurrent CRS?","options":[{"name":"Yes","response":"Evaluate and treat for other causes of fever, hypoxia, and hypotension\\nConsider laboratory testing to monitor for disseminated intravascular coagulation, hematology parameters, as well as pulmonary, cardiac, renal, and hepatic function\\nConsider non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\n*Dexamethasone* or equivalent 20 mg IV every 6 hours\\n\\tIf raised ICP/cerebral edema is suspected, consider hyperventilation and hyperosmolar therapy.\\n\\t\\fGive high-dose *methylprednisolone* (1-2 g/day, repeat every 24 hours if needed; taper as clinically indicated), and consider neurology and/or neurosurgery consultation.\\tContinue corticosteroids use until the event is Grade 1 or less; taper steroids if total corticosteroid exposure is greater than 3 days\\nRule out other causes of neurological signs and symptoms. Provide supportive care.\\nIf cerebral edema is suspected, consider hyperventilation and hyperosmolar therapy\\n*Tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg).\\n\\tRepeat every 8 hours as needed if no clinical improvement\\tAfter 2 doses, consider alternative anti-cytokine agents (i.e. monoclonal antibodies targeting cytokines)\\tLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses\\nIntensive care unit level monitoring and supportive therapy\\rIf not improving after 24 hours or worsening neurologic toxicity,\\n\\tGive high-dose *methylprednisolone* (1-2 g/day, repeat every 24 hours if needed; taper as clinically indicated),\\tRepeat *tocilizumab* 8mg/kg IV over 1 hr (not to exceed 800 mg)\\t\\fRepeat every 8 hours as needed if no clinical improvement\\t\\fAfter 2 doses, consider alternative anti-cytokine agents (i.e. monoclonal antibodies targeting cytokines)\\t\\fLimit to a max of 3 doses in 24 hour period; maximum total of 4 doses"},{"name":"No","response":"Consider non-sedating anti-seizure prophylaxis with e.g. *levetiracetam*\\n*Dexamethasone* or equivalent 20 mg IV every 6 hours\\n\\tIf raised ICP/cerebral edema is suspected, consider hyperventilation and hyperosmolar therapy.\\t\\fGive high-dose methylprednisolone (1-2 g/day, repeat every 24 hours if needed; taper as clinically indicated), and consider neurology and/or neurosurgery consultation.\\tContinue corticosteroids use until the event is Grade 1 or less; taper steroids if total corticosteroid exposure is greater than 3 days\\nRule out other causes of neurological signs and symptoms. Provide supportive care\\nIf cerebral edema is suspected, consider hyperventilation and hyperosmolar therapy\\nIntensive care unit level monitoring and supportive therapy\\rIf not improving after 24 hours or worsening neurologic toxicity\\n\\tGive high-dose *methylprednisolone* (1-2 g/day, repeat every 24 hours if needed; taper as clinically indicated)"}]}}]}]}]}')},68:function(e,o,n){"use strict";n.r(o);var t,i,r,a,s,d,l,c,m,p=n(0),u=n.n(p),h=n(23),g=n.n(h),f=(n(56),n(11)),v=(n(57),n(80)),y=n(17),x=n.p+"static/media/half_logo.90d90486.jpg",b=n(81),w=n(75),I=n(3),j=n(4),C=n(70),k=n(71),O=j.b.div(t||(t=Object(I.a)(["\n    // scroll-padding-top: 0;\n    // scroll-margin-top: 0;\n    // position: fixed;\n    // overflow: hidden;\n    // overflow-x: auto;\n    width: 100%;\n    left: 0;\n"]))),V=j.b.img(i||(i=Object(I.a)(["\n    width: 4vw;\n    // width: 2%;\n    // height: 4vh;\n    margin-top: 1vh;\n    margin-bottom: 1vh;\n"]))),G=Object(j.b)(C.a)(r||(r=Object(I.a)(["\n    position: fixed;\n    z-index: 10;\n    width: 100%;\n    background-color: white;\n    top: 0;\n    // scroll-padding-top: 0;\n    // scroll-margin-top: 0;\n    // padding-bottom: 1vh;\n    padding-top: 1vh;\n    box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px, rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n    justify-content: center;\n    align-items: center;\n    // margin-bottom: 1%;\n    // margin-left: unset;\n    // margin-right: unset;\n"]))),z=j.b.span(a||(a=Object(I.a)(["\n    font-size: 6vw;\n    font-weight: bold;\n    font-family: sans-serif;\n    // background-color: #231f20;\n    // color: white;\n    // width: 100%;\n    // border-left: solid;\n    border-color: #231f20;\n    border-width: 2px;\n    // margin-left: 8px;\n    // padding-left: 8px;\n"]))),S=Object(j.b)(C.a)(s||(s=Object(I.a)(["\n    display: flex;\n    flex-direction: column;\n    // overflow: visible;\n    padding-bottom: 2vh;\n    padding-top: 2vh;\n    background-color: white;\n    box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px, rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n    justify-content: center;\n    // color: white;\n    // background-color: rgb(33 31 31 / 100%);\n    align-items: center;\n    position: fixed;\n    left:0;\n    bottom:0;\n    right:0;\n    \n"]))),R=Object(j.b)(k.a)(d||(d=Object(I.a)(["\n    margin-right: 1%;\n    \n    &:active {\n        background-color: gainsboro;\n        // background-size: 100%;\n        transition: background 0s;\n      }\n"]))),T=Object(j.b)(C.a)(l||(l=Object(I.a)(["\n    // position: unset;\n    overflow: auto;\n    // scroll-behavior: auto;\n    // overflow-y: scroll;\n    justify-content: center;\n    margin-top: 12vh;\n    margin-bottom: 9vh;\n"]))),L=j.b.div(c||(c=Object(I.a)(["\n    width: 100%;\n    // border-bottom: solid;\n    // border-color: rgb(33 31 31 / 100%);\n    // border-width: 1px;\n    // padding-bottom: 3%;\n"]))),A=j.b.div(m||(m=Object(I.a)(["\n    border-left: solid;\n    border-color: #231f20;\n    border-width: 1px;\n    margin-left: 8px;\n    padding-left: 8px;\n    height: 4vh;\n    // width: 2px;\n"]))),E=n(9),q=n(15),N=function(e,o){var n=null;if(o===[null])return null;var t,i=Object(q.a)(o);try{for(i.s();!(t=i.n()).done;){var r,a=t.value,s=Object(q.a)(e);try{for(s.s();!(r=s.n()).done;){var d=r.value;if(d.name===a){e=d,n=d;break}}}catch(l){s.e(l)}finally{s.f()}}}catch(l){i.e(l)}finally{i.f()}return n},D=function(e,o){e.push("".concat(window.location.pathname).concat(o,"/"))},M=function(e){var o=!(arguments.length>1&&void 0!==arguments[1])||arguments[1],n="";return e.includes("\xae")?n="\xae":e.includes("\u2122")&&(n="\u2122"),o?e.split(/\xae|\u2122/)[0]:e.split(/\xae|\u2122/)[0]+n},P=!1,Y="Number of visits";function F(){return Boolean(window.localStorage.getItem(Y))}function H(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:1;window.localStorage.setItem(Y,e)}function U(){return F()?parseInt(window.localStorage.getItem(Y)):-1}var B="User has spent time on website";function W(){window.localStorage.setItem(B,!0)}var K,J,_,$,Q,X=n(72),Z=n(84),ee=Object(j.b)(X.a)(K||(K=Object(I.a)(["\n  flex-direction: column;\n  width: 90%;\n  max-width: 700px;\n"]))),oe=Object(j.b)(Z.a)(J||(J=Object(I.a)(["\n  // display: flex;\n  flex-direction: row;\n  // background-color: red;\n  align-items: center;\n  // border: 2px solid rgba(0,0,0,.125);\n  box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px,\n    rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n  padding-top: 3%;\n  padding-bottom: 3%;\n\n  background-position: center;\n  transition: background 0.5s;\n\n  // &:hover {\n  //   background: lightgray radial-gradient(circle, transparent 1%, lightgray 1%)\n  //     center/15000%;\n  // }\n\n  &:active {\n    background-color: gainsboro;\n    // background-size: 100%;\n    transition: background 0s;\n  }\n"]))),ne=Object(j.b)(Z.a.Header)(_||(_=Object(I.a)(["\n  justify-content: space-between;\n  width: 100%;\n  display: flex;\n  align-items: center;\n  background-color: unset;\n  border-bottom: unset;\n"]))),te=j.b.div($||($=Object(I.a)(["\n  // justify-content: space-between;\n  display: flex;\n  flex-direction: column;\n  // align-items: center;\n  // background-color: unset;\n  // border-bottom: unset;\n"]))),ie=j.b.h4(Q||(Q=Object(I.a)(["\n  text-align: start;\n  margin-bottom: 0;\n"]))),re=n(1);function ae(e){var o=Object(E.g)(),n=e.data.drugs,t=[],i=function(e){return[e.split(/\xae|\u2122/)[0],e.split(/\xae|\u2122/)[1]]};n.sort((function(e,o){return e.name.localeCompare(o.name)}));var r,a=Object(q.a)(n);try{var s=function(){var e=r.value;t.push(Object(re.jsx)(oe,{onClick:function(){return D(o,"toxicitymanagement/".concat(e.name))},children:Object(re.jsx)(ne,{children:Object(re.jsxs)(te,{children:[Object(re.jsx)(ie,{children:i(e.name)[0]}),Object(re.jsx)("span",{children:i(e.name)[1]})]})})},"".concat(e.name," card")))};for(a.s();!(r=a.n()).done;)s()}catch(d){a.e(d)}finally{a.f()}return Object(re.jsx)(re.Fragment,{children:Object(re.jsx)(ee,{children:t})})}var se,de,le,ce,me=n(83),pe=n(73),ue=n(74),he=Object(j.b)(pe.a)(se||(se=Object(I.a)(["\n    color: #007bff;\n"]))),ge=Object(j.b)(ue.a)(de||(de=Object(I.a)(["\n    color: #007bff;\n"]))),fe=Object(j.b)(me.a)(le||(le=Object(I.a)(["\n    position: fixed;\n    width: 92vw;\n    left: 4vw;\n    z-index: 100;\n    background-color: rgba(255,255,255);\n    border-color: darkgray;\n    border-radius: 1rem;\n    top: 2rem;\n"]))),ve=Object(j.b)(me.a.Header)(ce||(ce=Object(I.a)(["\n    justify-content: space-between;\n    border-top-left-radius: 1rem;\n    border-top-right-radius: 1rem;\n"])));var ye=function(){var e=U()>3&&10!=U(),o=Object(p.useState)(!1),n=Object(y.a)(o,2),t=(n[0],n[1],Object(p.useState)(!0)),i=Object(y.a)(t,2),r=i[0],a=i[1];return Object(re.jsx)(re.Fragment,{children:function(){var e=window.navigator.userAgent.toLowerCase();return/iphone|ipad|ipod/.test(e)}()&&!("standalone"in window.navigator&&window.navigator.standalone)&&!e&&Object(re.jsxs)(fe,{show:r,onClose:function(){return a(!r)},children:[Object(re.jsx)(ve,{children:Object(re.jsx)("strong",{className:"me-auto",children:"Tip: Add Website to iPhone Home Screen"})}),Object(re.jsxs)(me.a.Body,{children:[" Tap the ",Object(re.jsx)("i",{children:"Share"})," icon (",Object(re.jsx)(he,{}),"), scroll down, and tap ",Object(re.jsx)("i",{children:"Add to Home Screen"})," (",Object(re.jsx)(ge,{}),")."]})]})})};var xe,be,we,Ie,je,Ce,ke,Oe=function(e){var o=F();setTimeout(W,1e4);var n=Object(E.g)(),t=Object(p.useState)(!0),i=Object(y.a)(t,2),r=i[0],a=i[1],s=Object(p.useState)(!1),d=Object(y.a)(s,2),l=d[0],c=d[1],m=function(){a(!1),H()},u=function(){a(!1),c(!0)},h=function(){return Object(re.jsxs)(re.Fragment,{children:[Object(re.jsxs)(b.a,{centered:!0,show:r&&!o,onHide:m,backdrop:"static",keyboard:!1,children:[Object(re.jsx)(b.a.Header,{children:Object(re.jsx)("h5",{children:"Are you a healthcare professional?"})}),Object(re.jsx)(b.a.Body,{children:Object(re.jsx)("h6",{children:"You are going to a website that contains clinical information and was created specifically for healthcare professionals."})}),Object(re.jsxs)(b.a.Footer,{children:[Object(re.jsx)(w.a,{variant:"secondary",onClick:u,children:"No"}),Object(re.jsx)(w.a,{variant:"primary",onClick:m,children:"Yes"})]})]}),Object(re.jsx)(b.a,{centered:!0,show:l,backdrop:"static",keyboard:!1,children:Object(re.jsx)(b.a.Body,{children:Object(re.jsx)("h5",{children:"This information is designed for healthcare professionals."})})})]})};return Object(re.jsxs)(O,{children:[Object(re.jsxs)(G,{children:[Object(re.jsx)(V,{src:x,alt:"logo"}),Object(re.jsx)(A,{}),Object(re.jsx)(z,{children:"CAR-T Toxicity Management"})]}),Object(re.jsx)(h,{}),Object(re.jsx)(T,{children:Object(re.jsx)(ae,Object(f.a)(Object(f.a)({},e),{},{data:e.data}))}),Object(re.jsx)(ye,{}),Object(re.jsx)(S,{children:Object(re.jsxs)(L,{onClick:function(){return D(n,"aboutus")},children:[Object(re.jsx)(R,{}),Object(re.jsx)("span",{children:"About Us"})]})})]})},Ve=n(76),Ge=Object(j.b)(C.a)(xe||(xe=Object(I.a)(["\n  // padding-bottom: 4%;\n  // padding-top: 4%;\n  // box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px,\n  //   rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n  // justify-content: center;\n  background-color: #231f20;\n  color: rgb(255 255 255 / 100%);\n  align-items: center;\n  position: fixed;\n  // position: sticky;\n  // position: -webkit-sticky;\n  width: 100%;\n  z-index: 10;\n  top: 0px;\n  border-bottom: solid;\n  border-color: #c8102e;\n\n  ",";\n"])),(function(e){return e.invisible&&Object(j.a)(be||(be=Object(I.a)(["\n      // display: none;\n      position: unset;\n    "])))})),ze=Object(j.b)(Ve.a)(we||(we=Object(I.a)(["\n  font-size: 190%;\n  margin-left: 15px;\n  position: absolute;\n\n  &:active {\n    color: gray;\n    // background-size: 100%;\n    transition: background 0s;\n  }\n"]))),Se=j.b.div(Ie||(Ie=Object(I.a)(["\n  // display: flex;\n  // flex-direction: column;\n  // margin: auto;\n  // width: 100%;\n  margin-top: 1em;\n  margin-bottom: 1em;\n  // margin-left: 15%;\n  margin-left: 60px;\n"]))),Re=j.b.div(je||(je=Object(I.a)(["\n  font-size: x-large;\n  margin: auto;\n  margin-top: 2%;\n  margin-bottom: 2%;\n"]))),Te=j.b.div(Ce||(Ce=Object(I.a)(["\n  font-size: x-large;\n  // margin: auto;\n  margin-bottom: 2%;\n  margin-top: 0;\n  padding-top: 0;\n  line-height: initial;\n"]))),Le=j.b.div(ke||(ke=Object(I.a)(["\n  font-size: smaller;\n  // margin: auto;\n  margin-top: 2%;\n  font-weight: 300;\n  text-align: start;\n"])));var Ae,Ee,qe=function(e){var o=M(e.data),n=e.subtitle,t=function(e){return e.split(/(?=\()/)[0]},i=Object(E.g)();return Object(re.jsx)(re.Fragment,{children:Object(re.jsxs)(Ge,{children:[Object(re.jsx)(ze,{onClick:function(){return i.goBack()}}),n?Object(re.jsxs)(Se,{children:[Object(re.jsx)(Le,{children:M(n)}),Object(re.jsx)(Te,{children:t(o)})]}):Object(re.jsx)(Re,{children:t(o)})]})})},Ne=j.b.ul(Ae||(Ae=Object(I.a)(["\n    margin-top: 10vh;\n"]))),De=j.b.li(Ee||(Ee=Object(I.a)(["\n    // width: 100%;\n    text-align: left;\n    // position: relative;\n    padding: 2%;\n    // margin-bottom: unset;\n"])));function Me(){var e=new Date(document.lastModified);return"".concat(e.getMonth()+1,"/").concat(e.getDate(),"/").concat(e.getFullYear())}var Pe,Ye,Fe,He,Ue,Be,We,Ke,Je=function(){return Object(re.jsxs)(re.Fragment,{children:[Object(re.jsx)(qe,{data:"About Us"}),Object(re.jsxs)(Ne,{children:[Object(re.jsx)(De,{children:"This website is designed to assist healthcare providers in CAR\u2013T Treatment Centers administering multiple CAR-T drugs."}),Object(re.jsx)(De,{children:'All information on this website/application is based on publicly published FDA package inserts linked in the "Toxicity Management" page.'}),Object(re.jsx)(De,{children:"We are not responsible for any misuse of any of the described drugs or any mistreatment done as a result of this website. This website is for information only, we are not dispensing treatment decisions."}),Object(re.jsxs)(De,{children:["This website was last updated on ",Me(),"."]}),Object(re.jsxs)(De,{children:["Please ",Object(re.jsx)("a",{href:"mailto:SDahiya@umm.edu?subject=Cartcellengine.com",children:"contact us"})," with any concerns regarding this website or opportunities for improvement. Do not include patient information, as we unable to weigh in on treatment decisions."]})]})]})},_e=n(27),$e=Object(j.b)(X.a)(Pe||(Pe=Object(I.a)(["\n  width: 90%;\n  justify-content: center;\n  flex-direction: column;\n  max-width: 700px;\n"]))),Qe=Object(j.b)(Z.a)(Ye||(Ye=Object(I.a)(["\n  // display: flex;\n  flex-direction: column;\n  // background-color: red;\n  // align-items: center;\n  // border: 2px solid rgba(0,0,0,.125);\n  box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px,\n    rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n  padding-top: 3%;\n  padding-bottom: 3%;\n\n  &:active {\n    background-color: gainsboro;\n    // background-size: 100%;\n    transition: background 0s;\n  }\n"]))),Xe=j.b.div(Fe||(Fe=Object(I.a)(["\n  text-align: end;\n  font-size: 10px;\n  color: gray;\n  padding-right: 8px;\n  padding-top: 12px;\n"]))),Ze=Object(j.b)(Z.a)(He||(He=Object(I.a)(["\n  // display: flex;\n  flex-direction: row;\n  // background-color: red;\n  align-items: center;\n  // border: 2px solid rgba(0,0,0,.125);\n  box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px,\n    rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n  padding: 4%;\n  border-radius: 25px;\n  margin-bottom: 3vh;\n  margin-left: 40vw;\n  height: 3.2em;\n  background-color: #ffcd00; \n  // background-color: #c8102e;\n  color: #231f20;\n  width: max-content;\n\n  &:active {\n    background-color: #d9b10f;\n    // background-size: 100%;\n    transition: background 0s;\n  }\n"]))),eo=Object(j.b)(C.a)(Ue||(Ue=Object(I.a)(["\n  justify-content: space-between;\n  align-items: center;\n  margin-top: 10vh;\n  flex-direction: column;\n  height: 90vh;\n"]))),oo=Object(j.b)(Z.a.Header)(Be||(Be=Object(I.a)(["\n  justify-content: space-between;\n  display: flex;\n  text-align: start;\n  background-color: unset;\n  border-bottom: unset;\n  width: 100%;\n    // display: flex;\n  flex-direction: column;\n"]))),no=j.b.h4(We||(We=Object(I.a)(["\n  text-align: start;\n  margin-bottom: 0;\n"])));j.b.div(Ke||(Ke=Object(I.a)(["\n  // justify-content: space-between;\n  display: flex;\n  flex-direction: column;\n  // align-items: center;\n  // background-color: unset;\n  // border-bottom: unset;\n"])));var to,io,ro,ao,so,lo,co,mo,po,uo,ho,go,fo,vo,yo,xo,bo,wo,Io,jo,Co,ko=function(e){var o,n=e.data,t=Object(E.h)().drugtype,i=N(n.drugs,[t]),r=i.gradeTypes,a=Object(E.g)(),s=[],d=Object(q.a)(r);try{var l=function(){var e=o.value;s.push(Object(re.jsx)("div",{onClick:function(){return D(a,e.name)},children:Object(re.jsxs)(Qe,{children:[Object(re.jsxs)(oo,{children:[Object(re.jsx)(no,{children:e.name.split(/(?=\()/)[0]}),Object(re.jsx)("span",{children:e.name.split(/(?=\()/)[1]})]}),Object(re.jsx)(Xe,{children:e.gradeSource})]})}))};for(d.s();!(o=d.n()).done;)l()}catch(c){d.e(c)}finally{d.f()}return Object(re.jsxs)(re.Fragment,{children:[Object(re.jsx)(qe,Object(f.a)(Object(f.a)({},e),{},{data:t})),Object(re.jsxs)(eo,{children:[Object(re.jsx)($e,{children:s}),Object(re.jsx)("a",{href:i.packageInsertURL,target:"_blank",rel:"noreferrer noopener",onClick:function(e){return e.stopPropagation()},children:Object(re.jsx)(Ze,{children:"FDA Package Insert"})})]})]})},Oo=n(82),Vo=n(78),Go=n(79),zo=n(77),So=Object(j.b)(Z.a)(to||(to=Object(I.a)(["\n  // display: flex;\n  // flex-direction: row;\n  // background-color: red;\n  // align-items: center;\n  // border: 2px solid rgba(0,0,0,.125);\n  // box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px, rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n  // border: solid 1px #007bff;\n  box-shadow: rgb(101 119 134 / 25%) 0px 0px 15px, rgb(101 119 134 / 11%) 0px 0px 3px 1px;\n  // margin-left: 8px;\n  // margin-right: 8px;\n  margin-top: 1px;\n"]))),Ro=Object(j.b)(So)(io||(io=Object(I.a)(["\n  margin-bottom: 1rem;\n"]))),To=j.b.ul(ro||(ro=Object(I.a)(["\n  margin-top: 0.5rem;\n  margin-bottom: 0.5rem;\n  padding-right: 16px;\n"]))),Lo=(Object(j.b)(Oo.a.Toggle)(ao||(ao=Object(I.a)(["\n  // font-size: 20px;\n  // margin-right: 1%;\n  // transform: rotate(0deg);\n  // transition: transform .2s ease-out;\n\n  ",";\n"])),(function(e){return e.active&&Object(j.a)(so||(so=Object(I.a)(["\n      background-color: blue;\n      color: white;\n    "])))})),Object(j.b)(zo.a)(lo||(lo=Object(I.a)(["\n  font-size: 20px;\n  margin-right: 1%;\n  transform: rotate(0deg);\n  transition: transform 0.2s ease-out;\n\n  ",";\n"])),(function(e){return e.activated&&Object(j.a)(co||(co=Object(I.a)(["\n      transform: rotate(180deg);\n    "])))}))),Ao=Object(j.b)(C.a)(mo||(mo=Object(I.a)(["\n  justify-content: center;\n  margin-top: 5.5em;\n"]))),Eo=Object(j.b)(Oo.a)(po||(po=Object(I.a)(["\n  width: 100%;\n  display: flex;\n  flex-direction: column;\n  justify-content: space-around;\n  // margin-top: 0.4em;\n"]))),qo=Object(j.b)(Z.a.Header)(uo||(uo=Object(I.a)(["\n  text-align: start;\n  justify-content: space-between;\n  display: flex;\n  align-items: center;\n  background-color: unset;\n  border-bottom: unset;\n  padding: 17px;\n  color: #007bff;\n\n//   background-position: center;\n//   transition: background 0.5s;\n\n//   &:focus {\n//     background: #007bff radial-gradient(circle, transparent 1%, #007bff 1%)\n//       center/15000%;\n//   }\n\n  &:active {\n    background-color: #d6eaff;\n    // background-size: 100%;\n    transition: background 0s;\n  }\n\n  ",";\n"])),(function(e){return e.active&&Object(j.a)(ho||(ho=Object(I.a)(["\n      background-color: #007bff;\n      color: white;\n\n      &:active {\n        background-color: #007bff;\n        // background-size: 100%;\n        transition: background 0s;\n      }\n    "])))})),No=j.b.div(go||(go=Object(I.a)(["\n  border: solid #007bff 1px;\n  border-radius: 4px;\n  color: #007bff;\n  padding: 2%;\n  width: 50%;\n  \n  &:active {\n    background-color: #d6eaff;\n    // background-size: 100%;\n    transition: background 0s;\n  }\n\n  ","\n"])),(function(e){return e.active&&Object(j.a)(fo||(fo=Object(I.a)(["\n      background-color: #007bff;\n      color: white;\n\n      &:active {\n        background-color: #007bff;\n        // background-size: 100%;\n        transition: background 0s;\n      }\n    "])))})),Do=Object(j.b)(Z.a.Body)(vo||(vo=Object(I.a)(["\n  background-color: #007bff;\n  text-align: start;\n  color: white;\n"]))),Mo=j.b.div(yo||(yo=Object(I.a)(["\n  font-size: 12px;\n  font-style: italic;\n"]))),Po=Object(j.b)(Vo.a)(xo||(xo=Object(I.a)(["\n  width: 100%;\n  text-align: left;\n  position: relative;\n  padding: 2%;\n  margin-bottom: unset;\n  color: black;\n  background-color: #ffcd00;\n"]))),Yo=Object(j.b)(Vo.a)(bo||(bo=Object(I.a)(["\n  width: 100%;\n  text-align: left;\n  padding: 2%;\n  margin-bottom: unset;\n  position: sticky;\n  position: -webkit-sticky;\n  border-radius: unset;\n  z-index: 10;\n  // top: 5em;\n\n  ",";\n"])),(function(e){return Object(j.a)(wo||(wo=Object(I.a)(["\n    top: ","em;\n  "])),e.top)})),Fo=Object(j.b)(Go.a)(Io||(Io=Object(I.a)(["\n  width: 100%;\n"]))),Ho=j.b.div(jo||(jo=Object(I.a)(['\n  // content: "";\n  // position: absolute;\n  // top: 0;\n  // width: 30px;\n  // height: 30px;\n  content: "";\n  position: absolute;\n  top: 0;\n  width: 18%;\n  height: 100%;\n  left: 82%;\n'])));Object(j.b)(C.a)(Co||(Co=Object(I.a)(['\n  // content: "";\n  // position: absolute;\n  // top: 0;\n  // width: 30px;\n  // height: 30px;\n  content: "";\n  display: inline-block;\n  top: 0;\n  width: 100%;\n  // height: 20%;\n  left: 0;\n'])));var Uo=function(e){var o,n=e.data,t=Object(E.h)(),i=t.drugtype,r=t.managementtype,a=N(N(n.drugs,[i]).gradeTypes,[r]),s=a.grades,d=a.gradeSource,l=Object(p.useState)(""),c=Object(y.a)(l,2),m=c[0],u=c[1],h=Object(p.useState)(""),g=Object(y.a)(h,2),v=g[0],x=g[1],b=Object(p.useState)(""),w=Object(y.a)(b,2),I=w[0],j=w[1],C=Object(p.useState)(""),k=Object(y.a)(C,2),O=k[0],V=k[1],G=[],z=Object(q.a)(s);try{var S=function(){var e=o.value;G.push(Object(re.jsxs)(So,{children:[Object(re.jsxs)(Oo.a.Toggle,{variant:"outline-primary",as:qo,active:e.name===v,eventKey:e.name,onClick:function(o){return function(e,o){m===o.name?u(""):(u(o.name),j(""),V(""),x(o.name))}(0,e)},children:[e.name,Object(re.jsx)(Lo,{activated:e.name===m}),Object(re.jsx)(Ho,{})]},"".concat(e.name," card")),Object(re.jsx)(Oo.a.Collapse,{eventKey:e.name,children:Object(re.jsx)(Do,{children:e.description})})]}))};for(z.s();!(o=z.n()).done;)S()}catch(K){z.e(K)}finally{z.f()}var R=N(s,[v]),T=[];if(R&&R.followup){var L,A=Object(q.a)(R.followup.options);try{var D=function(){var e=L.value;T.unshift(Object(re.jsx)(No,{variant:"outline-primary",active:e.name===I,onClick:function(){return j(e.name)},children:e.name},"".concat(e.name," option")))};for(A.s();!(L=A.n()).done;)D()}catch(K){A.e(K)}finally{A.f()}}var M=[];if(R&&R.followup&&""!==I&&N(R.followup.options,[I]).followup){var P,Y=Object(q.a)(N(R.followup.options,[I]).followup.options);try{var F=function(){var e=P.value;M.unshift(Object(re.jsx)(No,{variant:"outline-primary",active:e.name===O,onClick:function(){return V(e.name)},children:e.name},"".concat(e.name," option")))};for(Y.s();!(P=Y.n()).done;)F()}catch(K){Y.e(K)}finally{Y.f()}}var H=function(e){return e.split("(")[0]},U=function(e){var o,n=[],t=e.split(/\r/),i=[],r=Object(q.a)(t.entries());try{for(r.s();!(o=r.n()).done;){var a=Object(y.a)(o.value,2);a[0];i=(i=a[1].split(/\n/)).map((function(e,o){return e.trim()?e.includes("\t")?Object(re.jsx)(To,{children:e.split(/\t/).map((function(e,o){return e.trim()?e.includes("\f")?Object(re.jsx)(To,{children:e.split(/\f/).map((function(e,o){return e.trim()?B(e):null}))}):B(e):null}))}):B(e):null})),n.push(Object(re.jsx)(Ro,{children:Object(re.jsx)(To,{children:i})}))}}catch(K){r.e(K)}finally{r.f()}return n},B=function(e,o,n){var t,i=[],r=e.split(/(\*.*?\*)/g),a=Object(q.a)(r);try{for(a.s();!(t=a.n()).done;){var s=t.value;if(s.includes("*")){var d=Object(re.jsx)("strong",{children:s.replaceAll("*","")});i.push(d)}else i.push(s)}}catch(K){a.e(K)}finally{a.f()}return Object(re.jsx)("li",{children:i},"list item ".concat(o,"_").concat(n))},W=function(e){var o=Object(p.useRef)(),n=e.data,t=e.choice;return console.log(n),console.log(t),Object(re.jsxs)(Po,{variant:"success",ref:o,children:[Object(re.jsx)("h4",{children:"Recommended Treatment:"}),Object(re.jsx)(re.Fragment,{children:U(N(n,[t]).response)})]},"response")};return Object(re.jsxs)(re.Fragment,{children:[Object(re.jsx)(qe,Object(f.a)(Object(f.a)({},e),{},{data:r,subtitle:i})),Object(re.jsxs)(Ao,{children:[Object(re.jsxs)(Yo,{variant:"dark",top:"5.5",children:["Select Toxicity Grade:\xa0",Object(re.jsx)("strong",{children:v}),Object(re.jsxs)(Mo,{children:["(",d,")"]})]},"grade-prompt"),Object(re.jsx)(Eo,{children:G}),v&&(R.followup?Object(re.jsxs)(re.Fragment,{children:[Object(re.jsxs)(Yo,{variant:"dark",top:"9.2",children:[R.followup.name,"\xa0",Object(re.jsx)("strong",{children:H(I)})]},"followup-prompt"),Object(re.jsx)(Fo,{children:T}),I&&N(R.followup.options,[I]).followup?Object(re.jsxs)(re.Fragment,{children:[Object(re.jsxs)(Yo,{variant:"dark",top:"12.9",children:[N(R.followup.options,[I]).followup.name,"\xa0",Object(re.jsx)("strong",{children:H(O)})]},"followup-prompt2"),Object(re.jsx)(Fo,{children:M}),O&&Object(re.jsx)(W,Object(f.a)(Object(f.a)({},e),{},{data:N(R.followup.options,[I]).followup.options,choice:O}))]}):I&&Object(re.jsx)(W,Object(f.a)(Object(f.a)({},e),{},{data:R.followup.options,choice:I}))]}):v&&Object(re.jsx)(W,Object(f.a)(Object(f.a)({},e),{},{data:s,choice:v})))]})]})},Bo=n(66);function Wo(){return F()&&!P&&(H(U()+1),P=!0),Object(re.jsx)(_e.a,{children:Object(re.jsx)(v.a,{fluid:!0,className:"App",children:Object(re.jsxs)(E.d,{children:[Object(re.jsx)(E.b,{exact:!0,path:"/aboutus",component:Je}),Object(re.jsx)(E.b,{path:"/toxicitymanagement/:drugtype/:managementtype/",render:function(e){return Object(re.jsx)(Uo,Object(f.a)(Object(f.a)({},e),{},{data:Bo}))}}),Object(re.jsx)(E.b,{path:"/toxicitymanagement/:drugtype/",render:function(e){return Object(re.jsx)(ko,Object(f.a)(Object(f.a)({},e),{},{data:Bo}))}}),Object(re.jsx)(E.b,{exact:!0,path:"/",render:function(e){return Object(re.jsx)(Oe,Object(f.a)(Object(f.a)({},e),{},{data:Bo}))}}),Object(re.jsx)(E.b,{path:"/",children:Object(re.jsx)(E.a,{to:"/"})})]})})})}var Ko=Boolean("localhost"===window.location.hostname||"[::1]"===window.location.hostname||window.location.hostname.match(/^127(?:\.(?:25[0-5]|2[0-4][0-9]|[01]?[0-9][0-9]?)){3}$/));function Jo(e,o){navigator.serviceWorker.register(e).then((function(e){e.onupdatefound=function(){var n=e.installing;null!=n&&(n.onstatechange=function(){"installed"===n.state&&(navigator.serviceWorker.controller?(console.log("New content is available and will be used when all tabs for this page are closed. See https://cra.link/PWA."),o&&o.onUpdate&&o.onUpdate(e)):(console.log("Content is cached for offline use."),o&&o.onSuccess&&o.onSuccess(e)))})}})).catch((function(e){console.error("Error during service worker registration:",e)}))}var _o=function(e){e&&e instanceof Function&&n.e(3).then(n.bind(null,85)).then((function(o){var n=o.getCLS,t=o.getFID,i=o.getFCP,r=o.getLCP,a=o.getTTFB;n(e),t(e),i(e),r(e),a(e)}))};n(67);g.a.render(Object(re.jsx)(u.a.StrictMode,{children:Object(re.jsx)(Wo,{})}),document.getElementById("root")),function(e){if("serviceWorker"in navigator){if(new URL("",window.location.href).origin!==window.location.origin)return;window.addEventListener("load",(function(){var o="".concat("","/service-worker.js");Ko?(!function(e,o){fetch(e,{headers:{"Service-Worker":"script"}}).then((function(n){var t=n.headers.get("content-type");404===n.status||null!=t&&-1===t.indexOf("javascript")?navigator.serviceWorker.ready.then((function(e){e.unregister().then((function(){window.location.reload()}))})):Jo(e,o)})).catch((function(){console.log("No internet connection found. App is running in offline mode.")}))}(o,e),navigator.serviceWorker.ready.then((function(){console.log("This web app is being served cache-first by a service worker. To learn more, visit https://cra.link/PWA")}))):Jo(o,e)}))}}(),_o()}},[[68,1,2]]]);
//# sourceMappingURL=main.d23fc9bc.chunk.js.map